Check for updates

OPEN ACCESS

EDITED BY Alessandra Gambero, Pontifical Catholic University of Campinas, Brazil

REVIEWED BY Marjorie Reyes Farias, University of Barcelona, Spain Gervason A. S. Moriasi, Mount Kenya University, Kenya

*CORRESPONDENCE Baojiang Chen, 🛛 chenbaojiang@vip.sina.com

¹These authors have contributed equally to this work

RECEIVED 12 July 2023 ACCEPTED 19 September 2023 PUBLISHED 28 September 2023

CITATION

Zhao M, Wu F, Tang Z, Yang X, Liu Y, Wang F and Chen B (2023), Antiinflammatory and antioxidant activity of ursolic acid: a systematic review and meta-analysis. *Front. Pharmacol.* 14:1256946. doi: 10.3389/fphar.2023.1256946

COPYRIGHT

© 2023 Zhao, Wu, Tang, Yang, Liu, Wang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or

reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Anti-inflammatory and antioxidant activity of ursolic acid: a systematic review and meta-analysis

Man Zhao^{1†}, Fengyang Wu^{1†}, Zhaohong Tang^{2†}, Xinyu Yang¹, Yanhua Liu¹, Fengxia Wang¹ and Baojiang Chen^{1*}

¹College of Animal Science and Technology, Hebei Agricultural University, Baoding, China, ²Hebei Research Institute of Microbiology Co., Ltd., Baoding, China

Introduction: There is currently evidence suggesting that ursolic acid may exert a favorable influence on both anti-inflammatory and antioxidant impact. Nevertheless, the anti-inflammatory and antioxidant activities of ursolic acid have not been systematically evaluated. Consequently, this study aims to conduct a systematic review and meta-analysis regarding the impact of ursolic acid on markers of inflammatory and antioxidant activity in both animal models and *in vitro* systems.


Methods: The search encompassed databases such as PubMed, Web of Science, Google Scholar, and ScienceDirect, up until May 2023. All eligible articles in English were included in the analysis. Standard mean difference (SMD) was pooled using a random-effects model, and the included studies underwent a thorough assessment for potential bias.

Results: The final review comprised 31 articles. In disease-model related studies, animal experiments have consistently shown that ursolic acid significantly reduced the levels of inflammatory parameters IL-1 β , IL-6 and TNF- α in mouse tissues. In vitro studies have similarly showed that ursolic acid significantly reduced the levels of inflammatory parameters IL-1 β , IL-6, IL-8 and TNF- α . Our results showed that ursolic acid could significantly elevate SOD and GSH levels, while significantly reducing MDA levels in animal tissues. The results of *in vitro* studies shown that ursolic acid significantly increased the level of GSH and decreased the level of MDA.

Discussion: Findings from both animal and *in vitro* studies suggest that ursolic acid decreases inflammatory cytokine levels, elevates antioxidant enzyme levels, and reduces oxidative stress levels (graphical abstract). This meta-analysis furnishes compelling evidence for the anti-inflammatory and antioxidant properties of ursolic acid.

KEYWORDS

ursolic acid, antioxidants, anti-inflammatory, in vitro, animals, meta-analysis



1 Introduction

Inflammation and oxidative stress play pivotal roles in the pathophysiology of numerous prevalent diseases, including diabetes, cardiovascular diseases, metabolic disorders, and cancer (Valko et al., 2007; Sarapultsev et al., 2015; Nakamura and Smyth, 2017; Burgos-Morón et al., 2019). In recent years, research focused on natural extracts and their bioactive constituents to mitigate inflammatory damage and ameliorate oxidative stress has gradually increased. These investigations consistently underscore the significant research and practical implications of natural extracts in mitigating the detrimental effects of inflammation and oxidative stress and reducing disease incidence (Liu et al., 2016; Moudgil and Venkatesha, 2022).

Triterpenoids are widely distributed throughout the plant kingdom, existing either as free acids or saponins in the form of sapogenins. They belong to a group of compounds long recognized for their diverse biological effects (Máñez et al., 1997). Ursolic acid, a naturally occurring pentacyclic triterpene carboxylic acid, is predominantly found in various plants, including rosemary, chasteberry, hawthorn, cranberry, and loquat leaves (Kashyap et al., 2016). Despite once being considered biologically inactive, it has garnered increasing interest in recent years due to its pharmacological potential (Kim et al., 2015; Kashyap et al., 2016; López-Hortas et al., 2018). Studies have demonstrated that ursolic acid has a broad spectrum of biological activities, including its ability to combat tumor cells and modulate lipid metabolism (Woźniak et al., 2015). Several studies have collectively affirmed the anti-inflammatory and antioxidant properties of ursolic acid (Lin et al., 2017; Li et al., 2018a). However, while several narrative review studies have explored the pharmacological effects of ursolic acid, they have not undertaken quantitative synthesis and have solely incorporated published findings (Habtemariam, 2019; Nguyen et al., 2021; Luan et al., 2022; Namdeo et al., 2023). In addition, a review of the anti-inflammatory effect of ursolic acid showed that the effects of ursolic acid on normal cells and tissues are occasionally pro-inflammatory, portraying it as a double-edged sword with both positive and negative consequences (Ikeda et al., 2008). Collectively, these studies underscore the need for a comprehensive assessment of the anti-inflammatory and antioxidant effects of ursolic acid, as well as its performance across different health conditions within the body. Systematic reviews and metaanalyses are aimed at reducing the bias of narrative reviews by identifying, appraising, and synthesizing all relevant literature, following a transparent and reproducible methodology to obtain the most reliable evidence.

Therefore, we conducted a comprehensive systematic review and meta-analysis encompassing all relevant *in vitro* and *in vivo* studies. We examined the influence of ursolic acid on the body's health status and its role in chronic inflammatory and oxidative stress-related pathological conditions. Our objective was to ascertain whether ursolic acid possesses the capability to modulate inflammatory responses and oxidative stress.

2 Methods

2.1 Literature search strategy and selection criteria

This meta-analysis strictly followed the guidelines of the Preferred Reporting Items for Systematic Reviews and Metaanalyses (PRISMA) (Moher et al., 2015).

Three researchers independently searched PubMed, Web of Science, Google Scholar and ScienceDirect (before 6 May 2023). We restricted the language to English. The MeSH term "ursolic acid, or any name of ursolic acid, in combination with "antioxidants" or "anti-inflammatory" to identify eligible studies.

2.2 Inclusion and exclusion criteria

The search results from the four databases (PubMed, Web of Science, Google Scholar and ScienceDirect) were pooled in EndNote (Version X9). Duplicate publications (n = 1,407) were subsequently removed. For inclusion in our meta-analysis, studies had to meet the following criteria: 1) manuscripts published in English in peerreviewed journals, 2) experimental trials and randomized control

trials (RCTs), 3) studies including ursolic acid treatment and negative control groups and use of ursolic acid to treat chronic inflammatory and oxidative stress system lesions *versus* intervention control group, and 4) reporting of anti-inflammatory or antioxidant activity.

The exclusion criteria were defined as follows: 1) the major content of the supplement was not ursolic acid, 2) studies lacking data on anti-inflammatory or antioxidant activity, and 3) studies that were not of RCTs. Following these criteria, we conducted a selective screening of eligible studies for inclusion in the analysis.

2.3 Data extraction

The information extracted from the included studies was as follows: first author, year, country, experimental subject, sample, sample size, intervention, dosage, duration, and primary outcomes. Primary outcomes include: interleukin-1beta (IL-1 β), tumor necrosis factor-alpha (TNF- α), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), glutathione (GSH), glutathione peroxidase (GPx), catalase (CAT), superoxide dismutase (SOD), malondialdehyde (MDA). When results were available only in graphical format, data were extracted using Origin (Version 2022).

2.4 Study quality assessment

Two investigators (M.Z. and F.Y.W.) performed independent study quality assessment according to the criteria provided in the Consolidated Standards of Reporting Trials statement (Moher et al., 2015) and the Cochrane Collaboration's tool for assessing risk of bias (Higgins et al., 2011). The assessment items included random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other bias. The divergences were resolved by the third investigator (Z.H.T.).

2.5 Statistical analysis

2.5.1 Meta-analysis

The statistical analysis was performed with R 4.1.2 in the meta package (Balduzzi et al., 2019). The random-effects model was used to estimate the effect size and 95% confidence interval (CI) for each trait (Riley et al., 2011; Eng et al., 2014). The effect size of ursolic acid was expressed as standard mean difference (SMD). We used the I^2 statistic to quantitatively measure the heterogeneity in our analysis. Heterogeneity between-study variability was assessed using the I^2 : no heterogeneity, $I^2 \le 25\%$; low heterogeneity, $25\% < I^2 \le 50\%$; moderate heterogeneity, $50\% < I^2 \le 75\%$; and high heterogeneity, $I^2 > 75\%$ (Higgins et al., 2003).

2.5.2 Meta-regression analysis

We conducted meta-regression analyses to elucidate significant heterogeneity (p < 0.05) or beyond a moderate level ($I^2 > 50\%$) (Higgins et al., 2003). To avoid a false positive result, the regression analysis was applied only to groups with more than 10 records.

Meta-regression analyses were conducted using effect sizes (SMD) for each outcome (P_{SMD} <0.05, I^2 > 50%, n ≥ 10) as the dependent variable to examine heterogeneity sources of meta-analysis.

2.5.3 Subgroup categorization and analysis

We conducted subgroup analyses to elucidate significant heterogeneity (p < 0.05) or beyond a moderate level ($I^2 > 50\%$) (Higgins et al., 2003). The sub-groups were divided based on the original categories and practical implications where necessary.

2.5.4 Publication bias

Publication bias was evaluated using Egger's tests ($n \ge 5$), for which the significance level was defined at p < 0.05 (Egger et al., 1997).

3 Results

3.1 Selection of studies

The process and results of the publication search and selection are shown in Figure 1. A total of 2,942 articles were identified, with 695 from PubMed, 1,859 from Web of Science, 94 from Google Scholar, and 294 from ScienceDirect. After removing duplicate articles, we proceeded to read the remaining 1,535 titles and abstracts. After excluding published in non-English, reviews, letters and those whose theme did not match the criteria of this study, 103 articles remained. An additional 72 articles were excluded after a full-text review based on previous protocols. Finally, 31 articles were included in this meta-analysis. The main characteristics of the 31 studies are provided in Supplementary Tables S1, S2. The bias risks for each study and overall are shown in Figure 2, Figure 3.


3.2 Animal studies


3.2.1 The effect of use of ursolic acid to treat chronic inflammatory and oxidative stress system lesions

In animal studies, we analyzed the effect of the use of ursolic acid to treat chronic inflammatory and oxidative stress system lesions on inflammatory markers. As shown in Figure 4, ursolic acid significantly reduced the content of IL-1 β (SMD = -4.07, 95%CI: -5.59 to -2.54, $P_{\text{SMD}} < 0.0001$, $I^2 = 79\%$), IL-6 (SMD = -4.53, 95% CI: -6.83 to -2.23, $P_{\text{SMD}} < 0.0001$, $I^2 = 86\%$) and TNF- α (SMD = -2.65, 95%CI: -3.67 to -1.63, $P_{\text{SMD}} < 0.0001$, $I^2 = 75\%$).

We analyzed the effects of the use of ursolic acid to treat chronic inflammatory and oxidative stress system lesions on oxidative stress markers. As shown in Figure 5, ursolic acid significantly increased the content of SOD (SMD = 3.62, 95%CI: 1.97 to 5.26, $P_{\rm SMD}$ < 0.0001, I^2 = 86%) and GSH (SMD = 8.01, 95%CI: 4.41 to 11.61, $P_{\rm SMD}$ < 0.0001, I^2 = 86%). Ursolic acid significantly reduced the content of MDA (SMD = -2.28, 95%CI: -2.91 to -1.66, $P_{\rm SMD}$ < 0.0001, I^2 = 71%).


We conducted meta-regression analyses, incorporating covariates such as dosage (mg/kg), duration (d) and intervention. The results showed that dosage had a significant impact on IL-1 β (*p* = 0.026), while duration significantly influenced SOD (*p* = 0.002)





(Table 1). However, the intervention had no significant effect on IL-1 β , MDA TNF- α and SOD (p > 0.05). Furthermore, we conducted a sub-group analysis based on dosage categories (Low: <25 mg/kg; Middle: 25–50 mg/kg; High: > 50 mg/kg) and duration (Short (\leq 14 days); Long: >14 days). The sub-group analysis indicated that all three dosage groups of ursolic acid had significant effects on IL-1 β ($P_{\text{SMD}} < 0.05$), and there was a significant difference among the three subgroups (Q = 12.05, p = 0.002), the low-dosage group had the best effect (SMD = -5.91, 95%CI: -8.17 to -3.65, $P_{\text{SMD}} < 0.001$)

(Table 2). Moderate heterogeneity was observed in the low-dosage group ($I^2 = 68\%$, p < 0.05), high heterogeneity was observed in the middle-dosage group ($I^2 = 77\%$, p < 0.05), and no heterogeneity was observed in the high-dosage group ($I^2 = 0\%$, p = 0.51). All two duration groups of ursolic acid had significant effects on SOD ($P_{\rm SMD} < 0.05$), but there was no significant difference between the two subgroups (p = 0.26). No heterogeneity was observed in the short-duration group ($I^2 = 49\%$, p = 0.16), and high heterogeneity was observed in the long-duration group ($I^2 = 10\%$, $I^2 = 10\%$



86%, p < 0.05). Additionally, the results of Egger's test indicated some evidence of publication bias in IL-1 β , IL-6, MDA, SOD, TNF- α and GSH(p < 0.05) (Table 3).

3.3 In vitro studies

3.3.1 The effect of ursolic acid on antiinflammatory and antioxidant parameters

As shown in Figure 6, ursolic acid did not significantly affect IL-1 β , IL-6, SOD, GSH, GPx and CAT in healthy cells ($P_{SMD} > 0.05$). The Egger's test results indicated no evidence of publication bias in IL-1 β and IL-6 (p > 0.05).

3.3.2 The effect of use of ursolic acid to treat chronic inflammatory and oxidative stress system lesions

We conducted an analysis to evaluate the impact of ursolic acid in treating chronic inflammatory and oxidative stress system lesions on inflammatory markers within cells. As shown in Figure 7, ursolic acid significantly reduced the content of IL-1 β (SMD = -5.89, 95% CI: -8.24 to -3.54, $P_{\text{SMD}} < 0.0001$, $I^2 = 60\%$), IL-6 (SMD = -4.64, 95%CI: -6.14 to -3.14, $P_{\text{SMD}} < 0.0001$, $I^2 = 59\%$), IL-8 (SMD = -6.43, 95%CI: -8.91 to -3.94, $P_{\text{SMD}} < 0.0001$, $I^2 = 53\%$) and TNF- α (SMD = -2.46, 95%CI: -3.26 to -1.67, $P_{\text{SMD}} < 0.0001$, $I^2 = 45\%$).

We analyzed the effects of the use of ursolic acid to treat chronic inflammatory and oxidative stress system lesions on oxidative stress markers in cells. As shown in Figure 8, ursolic acid did not significantly affect withers SOD, GPx and CAT ($P_{\text{SMD}} > 0.05$). Ursolic acid significantly reduced the content of MDA (SMD = -7.16, 95%CI: -9.04 to -5.29, $P_{\text{SMD}} < 0.0001$, $I^2 = 6\%$). Ursolic acid significantly increased the content of GSH (SMD = 2.85, 95%CI: 2.02 to 3.69, $P_{\text{SMD}} < 0.0001$, $I^2 = 27\%$).

We performed meta-regression analyses, including two covariates: dosage (μ M) and duration (h). The results revealed that dosage had a significant effect on IL-8 (p = 0.004) but no significant effect on IL-1 β , IL-6 and TNF- α (p > 0.05). On the other hand, duration had a significant effect on IL-1 β (p < 0.0001) but no significant effect on IL-6, IL-8 and TNF- α (p > 0.05) (Table 1).

Subsequently, we conducted sub-group analyses for these two covariates, with dosage categorized as Low: <10 µM, Middle: 10-19 µM, High: >19 µM; and duration as Short: <20 h, Middle: 20-40 h, Long: >40 h). Sub-group analysis indicated that all three duration groups of ursolic acid had significant effects on IL-1ß (P_{SMD} <0.05), Notably, there was a significant difference among the three subgroups (Q = 18.56, p < 0.0001), with the long-duration group demonstrating the most favorable effect (SMD = -10.28, 95%CI: -15.80 to -4.76, P_{SMD} < 0.0001) (Table 2). No heterogeneity was observed in three duration groups (Short: $I^2 = 45\%$, Middle: $I^2 = 0\%$, Long: $I^2 = 0\%$; p > 0.05). Furthermore, the sub-group analysis indicated that all three dosage groups of ursolic acid had significant effects on IL-8 (P_{SMD}<0.05), Similarly, there was a significant difference among the three subgroups (Q = 6.09, p =0.048), with the high dosage group had the best effect $(SMD = -14.00, 95\%CI: -21.15 \text{ to } -6.86, P_{SMD} = 0.0001)$ (Table 2). No heterogeneity was observed in three dosage groups (Short: $I^2 = 48\%$, Middle: $I^2 = 0\%$, Long: $I^2 = 38\%$; p > 0.05). Finally, the results of Egger's test indicated some evidence of publication bias in IL-1 β , IL-6, IL-8, IL-10, MDA and TNF- α (p < 0.05) (Table 3), while no evidence of publication bias was found in SOD, GSH, GPx and CAT (p > 0.05).

4 Discussion

This meta-analysis aims to comprehensively evaluate the impact of ursolic acid on enhancing anti-inflammatory and antioxidant functions while identifying potential influencing factors on effect size. The findings hold substantial potential for optimizing the application of ursolic acid, which carries significant implications for preventing and treating diseases related to inflammatory and oxidative stress systems. Distinguished from previous studies, our systematic review encompassed multiple databases and, as far as possible, conducted quantitative syntheses. To the best of our knowledge, this is currently a rare comprehensive meta-analysis of this issue. This systematic review and meta-analysis of 31 trials suggests that ursolic acid has a significant beneficial effect in the treatment of inflammatory and oxidative stress.

	E	xperim	ental		Control	I	Standardised Mean			Weight	Weight	
Study	Total	Mean	SD	Tota	l Mean	SD	Difference	SMD	95%-CI	(common)	(random)	P-value
Benincá 2011	5	626.00	129.02	5	1156.00	266.09		-2.29	[-4.06; -0.52]	10.5%	10.6%	
Chen 2012	10	68.79	14.01	10	152.87	14.01		-5.75	[-7.91; -3.59]	7.0%	9.9%	
Jang 2014(4)	6	36.13	12.90	6	161.29	16.78	!	-7.72	[-11.60; -3.83]	2.2%	6.9%	
Jang 2014(5)	6	25.81	2.58	6	161.29	16.78		-10.41	[-15.56; -5.27]	1.2%	5.1%	
Leng 2016(2)	5	36.16	4.79	5	59.20	3.35		-5.03	[-8.08; -1.99]	3.5%	8.3%	
Leng 2016(3)	10	187.73	70.66	9	299.45	114.91		-1.13	[-2.12; -0.15]	33.8%	11.8%	
Jia 2021(1)	6	209.71	23.30	6	436.89	43.69	<u> </u>	-5.99	[-9.09; -2.89]	3.4%	8.2%	
Jia 2021(2)	6	189.32	32.04	6	436.89	43.69	<u> </u>	-5.96	[-9.05; -2.87]	3.5%	8.2%	
Liu 2022(1)	6	160.34	20.25	6	283.54	52.32		-2.87	[-4.65; -1.08]	10.3%	10.6%	
Liu 2022(2)	6	210.97	50.63	6	283.54	52.32	: :=	-1.30	[-2.59; -0.01]	19.7%	11.4%	
Rong 2022	3	27.34	1.95	3	34.77	3.12		-2.28	[-4.89; 0.34]	4.8%	9.1%	
Common effe	ct mod	del 6	9		6	8	\$	-2.58	[-3.15; -2.00]	100.0%		<0.0001
Random effect	ts mo	del					•	-4.07	[-5.59; -2.54]		100.0%	< 0.0001

B IL-6

	E	xperime	ntal		Control		Standardised Mean			Weight	Weight	
Study	Total	Mean	SD	Total	Mean	SD	Difference	SMD	95%-CI	(common)	(random)	P-value
Chen 2012	10	1019.11	76.43	10	1745.22	101.91	: :	-7.72	[-10.51; -4.93]	6.8%	14.0%	
Jang 2014(4)	6	5.61	2.32	6	18.58	3.29		-4.20	[-6.52; -1.88]	9.8%	14.9%	
Jang 2014(5)	6	3.48	3.10	6	18.58	3.29	<u> </u>	-4.36	[-6.74; -1.97]	9.3%	14.8%	
Wang 2018 b(1) 6	700.35	102.42	6	843.21	187.76	· · · · · · · · · · · · · · · · · · ·	-0.87	[-2.08; 0.34]	36.2%	16.8%	
Wang 2018 b(2) 6	560.98	204.83	6	843.21	187.76	· · · · · · · · · · · · · · · · · · ·	-1.33	[-2.62; -0.03]	31.2%	16.6%	
Jia 2021(1)	6	236.89	66.02	6	660.19	42.72	;	-7.02	[-10.59; -3.46]	4.1%	12.4%	
Jia 2021(2)	6	205.83	50.49	6	660.19	42.72	i	-8.96	[-13.43; -4.50]	2.6%	10.6%	
Common effec	t moc	lel 46			4	6	\$	-2.59	[-3.32; -1.87]	100.0%		<0.0001
Random effect	s mo	del						-4.53	[-6.83; -2.23]		100.0%	0.001
Heterogeneity: I ²	= 86%	$6, t^2 = 7.8$	408, <i>p</i> < 0	0.01			-10 -5 0 5	10				

NF-α	E	kperimer	ntal		Contro	l	Standardised Mean			Weight	Weight	
Study	Total	Mean	SD	Tota	Mean	SD	Difference	SMD	95%-CI	(common)		P-value
Benincá 2011	5	1032.00	54.11	5	2945.00	847.47	<u> </u>	-2.88	[-4.89; -0.86]	4.3%	7.4%	
Chen 2012	10	93.35	6.33	10	178.80	14.24	: : :	-7.43	[-10.12; -4.73	2.4%	6.0%	
Jang 2014(4)	6	61.94	21.29	6	191.61	42.58		-3.55	[-5.61; -1.50]	4.1%	7.4%	
Jang 2014(5)	6	42.58	11.61	6	191.61	42.58		-4.41	[-6.81; -2.00]	3.0%	6.6%	
Wang 2018 b(1)	6	189.55	92.18	6	264.81	136.56	÷ •	-0.60	[-1.76; 0.57]	12.7%	9.2%	
Wang 2018 b(2)	6	140.77	61.45	6	264.81	136.56	÷ 💼 -	-1.08	[-2.33; 0.16]	11.2%	9.1%	
Peshattiwar 2020(1)	10	4.07	0.42	10	5.83	2.11		-1.11	[-2.06; -0.15]	19.0%	9.6%	
Peshattiwar 2020(2)	10	4.10	2.11	10	5.83	2.11	· •	-0.79	[-1.70; 0.13]	20.6%	9.7%	
Jia 2021(1)	6	330.10	42.72	6	559.22	58.25		-4.14	[-6.43; -1.85]	3.3%	6.8%	
Jia 2021(2)	6	279.61	46.60	6	559.22	58.25		-4.89	[-7.51; -2.28]	2.5%	6.2%	
Liu 2022(1)	6	244.07	32.20	6	327.12	30.51		-2.44	[-4.08; -0.81]	6.5%	8.3%	
Liu 2022(2)	6	276.27	23.73	6	327.12	30.51		-1.72	[-3.12; -0.32]	8.8%	8.7%	
Rong 2022	3	69.05	5.56	3	89.68	4.76		-3.18	[-6.48; 0.12]	1.6%	5.0%	
							1					
Common effect mod		86			86		\$	-1.77	[-2.18; -1.35			<0.000
Random effects mod	let							-2.65			100.0%	<0.000
Heterogeneity: $I^2 = 75\%$	$\dot{\tau}$	2.5831, <i>p</i>	< 0.01			-	10 -5 0	5	10			

FIGURE 4

Characteristic of animal studies regarding the effect of use of ursolic acid to treat chronic inflammatory and oxidative stress system lesions on inflammatory markers. Interleukin-1beta (IL-1 β) (A), Interleukin-6 (IL-6) (B) and (Tumor necrosis factor-alpha) TNF- α (C).

In the context of an inflammatory response, there is a noticeable increase in the expression and release of pro-inflammatory cytokines. The excessive production of these inflammatory factors stands as a primary driver of tissue damage. Among the key pro-inflammatory cytokines, IL-1 and TNF- α occupy prominent roles. TNF- α , as the initiating cytokine in the inflammatory process, triggers cascading

effects that stimulate the upregulation of other inflammatory factors such as IL-1 and IL-6, thereby amplifying the overall inflammatory response (Dinarello, 2005; Hovhannisyan et al., 2011; Bent et al., 2018; Pandolfi et al., 2020; Bernhard et al., 2021; van Loo and Bertrand, 2023). In disease-model-related studies, animal experiments have consistently shown that ursolic acid significantly reduced the levels

	E	perime	ntal		Control		Standardised Mean			Weight	Weight	
Study	Total	Mean	SD	Total	Mean	SD	Difference	SMD	95%-CI	0	0	P-value
Ma 2014(1)	7	281.60	9.60	7	209.60	12.80	i <u></u>	5.96	[3.18; 8.74]	3.2%	9.2%	
Ma 2014(2)	7	332.53	16.06	7	209.60	12.80		7.92	[4.34; 11.51]	1.9%	7.8%	
He 2015(1)	5	200.73	3.65	5	124.09	20.44	 	4.71	[1.83; 7.60]	2.9%	9.0%	
He 2015(2)	5	245.26	37.23	5	124.09	20.44	 •	3.64	[1.28; 6.01]	4.4%	9.9%	
Wang 2018 a	10	116.20	56.60	10	90.50	6.60	—	0.61	[-0.29; 1.51]	30.1%	12.0%	
Xu 2018	8	100.81	15.58	8	78.41	14.12		1.42	[0.29; 2.55]	19.1%	11.8%	
Zahra 2020	8	258.92	4.98	8	227.39	8.30	! <u> </u>	4.35	[2.37; 6.34]	6.2%	10.5%	
Jia 2021(1)	6	149.25	30.15	6	46.73	13.57		4.05	[1.79; 6.30]	4.8%	10.1%	
Jia 2021(2)	6	176.38	19.60	6	46.73	13.57	· · · · ·	7.10	[3.50; 10.70]	1.9%	7.8%	
Pordanjani 202	28	4.62	3.77	8	4.47	3.21	ŧ	0.04	[-0.94; 1.02]	25.5%	11.9%	
Common effect	t mod	lel 70)		70		\$	1.70	[1.21; 2.20]	100.0%		< 0.0001
Random effec	ts mo	del						3.62	[1.97; 5.26]		100.0%	<0.0001

B MDA

	Ex	perime	ntal		Contro	L	Standardised Me	ean		Weight	Weight	
Study	Total	Mean	SD	Total	Mean	SD	Difference	SMD	95%-CI	(common)	(random)	P-value
_u 2007	10	1.45	0.23	10	2.15	0.30	·불 	-2.51	[-3.74; -1.28]	7.0%	6.8%	
Yin 2012(1)	10	1.54	0.23	10	2.72	0.42		-3.34	[-4.78; -1.89]	5.0%	6.2%	
Yin 2012(2)	10	1.09	0.26	10	2.61	0.34		-4.81	[-6.68; -2.94]	3.0%	5.1%	
Chen 2012	10	2.44	0.57	10	3.72	0.54	÷.	-2.21	[-3.37; -1.05]	7.8%	7.1%	
Yang 2014	8	1.43	0.15	8	2.13	0.14	- ?	-4.56	[-6.61; -2.51]	2.5%	4.6%	
He 2015(1)	5	14.11	0.73	5	66.42	6.57	· —→	-10.10	[-15.82; -4.38]	0.3%	1.1%	
He 2015(2)	5	10.46	1.46	5	66.42	6.57	<u>→→→</u> 3 [-10.61	[-16.61; -4.62]	0.3%	1.0%	
Wang 2018a	10	4.87	1.50	10	9.67	3.80	<u>i</u>	-1.59	[-2.62; -0.56]	9.9%	7.4%	
Xu 2018	8	5.10	1.38	8	7.50	1.81	<u> </u>	-1.41	[-2.54; -0.28]	8.3%	7.1%	
Elshamy 2019	8	1.76	0.99	8	2.50	1.78	5 -	-0.49	[-1.48; 0.51]	10.5%	7.5%	
Peshattiwar 2020(1)	10	0.28	0.13	10	1.64	0.76		-2.39	[-3.59; -1.19]	7.3%	6.9%	
Peshattiwar 2020(2)	10	0.25	0.24	10	1.64	0.76	-	-2.36	[-3.56; -1.17]	7.4%	6.9%	
Jia 2021(1)	6	112.50	22.50	6	187.50	26.25		-2.83	[-4.60; -1.06]	3.3%	5.3%	
Jia 2021(2)	6	130.65	35.18	6	187.50	26.25	*	-1.69	[-3.08; -0.30]	5.4%	6.4%	
Liu 2022(1)	6	1.83	0.70	6	3.30	1.00		-1.57	[-2.93; -0.21]	5.7%	6.5%	
Liu 2022(2)	6	2.04	0.43	6	3.30	1.00	長	-1.51	[-2.86; -0.17]	5.8%	6.5%	
Pordanjani 2022	8	38.11	32.87	8		21.40	· · · · · · · · · · · · · · · · · · ·	-0.52	[-1.53; 0.48]	10.5%	7.5%	
Common effect mo	del	136			136		0 0	-1.93	[-2.25; -1.60]	100.0%		<0.000
Random effects mo	del						· · · · ·	-2.28	[-2.91; -1.66]		100.0%	<0.000
Heterogeneity: $I^2 = 71^{\circ}$	%, 7 =	1.0875,	p < 0.01				-15 -10 -5 0 5 1	0 15				

Exp	perimer	ntal		Control	i.	Standardised Mean			Weight	Weight	
Total	Mean	SD	Total	Mean	SD	Difference	SMD	95%-CI			P-value
10	4.78	0.28	10	2.02	0.13	:	12.11	[7.86; 16.36]	8.3%	18.1%	
10	5.80	0.31	10	2.19	0.21		13.06	[8.49; 17.63]	7.2%	17.4%	
7	12.12	0.69	7	9.82	0.67	 ¦:	3.17	[1.44; 4.89]	50.6%	22.9%	
7	13.58	0.36	7	9.82	0.67		6.54	[3.53; 9.56]	16.5%	20.7%	
8	11.57	0.56	8	8.19	0.32		7.01	[4.07; 9.95]	17.4%	20.8%	
ct mod	lel 4	2		42		\$	5.85	[4.62; 7.07]	100.0%		<0.0001
ts mor	del						8.01	[4.41; 11.61]		100.0%	<0.0001
² = 86%	6, 2 = 13	3.9405, <i>j</i>	o < 0.01	2	15 –10	-5 0 5 10 15					
	Total 10 10 7 8 ct mod	Total Mean 10 4.78 10 5.80 7 12.12 7 13.58 8 11.57 ct model 4 ets model 4	10 4.78 0.28 10 5.80 0.31 7 12.12 0.69 7 13.58 0.36 8 11.57 0.56 ct model 42 cts model 42	Total Mean SD Total 10 4.78 0.28 10 10 5.80 0.31 10 7 12.12 0.69 7 7 13.58 0.36 7 8 11.57 0.56 8 ct model 42	Total Mean SD Total Mean 10 4.78 0.28 10 2.02 10 5.80 0.31 10 2.19 7 12.12 0.69 7 9.82 7 13.58 0.36 7 9.82 8 11.57 0.56 8 8.19 ct model 42 42 42	Total Mean SD Total Mean SD 10 4.78 0.28 10 2.02 0.13 10 5.80 0.31 10 2.19 0.21 7 12.12 0.69 7 9.82 0.67 7 13.58 0.36 7 9.82 0.67 8 11.57 0.56 8 8.19 0.32 ct model 42 42 42	Total Mean SD Total Mean SD Difference 10 4.78 0.28 10 2.02 0.13 Image: constraint of the set interval	Total Mean SD Total Mean SD Difference SMD 10 4.78 0.28 10 2.02 0.13 1 12.11 13.06 10 5.80 0.31 10 2.19 0.21 13.06 13.17 7 13.58 0.36 7 9.82 0.67 6.54 3.17 7 13.58 0.36 7 9.82 0.67 6.54 5.85 8 11.57 0.56 8 8.19 0.32 7.01 1 ct model 42 42 5.85 8.01 8.01 8.01 8.01 8.01	Total Mean SD Total Mean SD Difference SMD 95%-Cl 10 4.78 0.28 10 2.02 0.13 12.11 [7.86; 16.36] 10 5.80 0.31 10 2.19 0.21 13.06 [8.49; 17.63] 7 13.58 0.36 7 9.82 0.67 3.17 [1.44; 4.89] 8 11.57 0.56 8 8.19 0.32 7.01 [4.07; 9.95] ct model 42 42 5.85 [4.62; 7.07] 8.01 [4.41; 11.61]	Total Mean SD Total Mean SD Difference SMD 95%-CI (common) 10 4.78 0.28 10 2.02 0.13 12.11 [7.86; 16.36] 8.3% 10 5.80 0.31 10 2.19 0.21 13.06 [8.49; 17.63] 7.2% 7 12.12 0.69 7 9.82 0.67 3.17 [1.44; 4.89] 50.6% 7 13.58 0.36 7 9.82 0.67 6.54 [3.53; 9.56] 16.5% 8 11.57 0.56 8 8.19 0.32 7.01 [4.07; 9.95] 17.4% ct model 42 42 42 8.01 [4.41; 11.61]	Total Mean SD Total Mean SD Difference SMD 95%-CI (common) (random) 10 4.78 0.28 10 2.02 0.13 1 12.11 [7.86; 16.36] 8.3% 18.1% 10 5.80 0.31 10 2.19 0.21 13.06 [8.49; 17.63] 7.2% 17.4% 7 12.12 0.69 7 9.82 0.67 6.54 [3.53] 9.56] 16.5% 22.9% 7 13.58 0.36 7 9.82 0.67 6.54 [3.53] 9.56] 16.5% 20.7% 8 11.57 0.56 8 8.19 0.32 7.01 [4.07; 9.95] 17.4% 20.8% ct model 42 42 5.85 [4.62; 7.07] 100.0% 8.01 [4.41; 11.61] 100.0% 100.0%

FIGURE 5

С

Characteristic of animal studies regarding the effect of use of ursolic acid to treat chronic inflammatory and oxidative stress system lesions on antioxidant markers. Malondialdehyde (MDA) (A) and Superoxide dismutase (SOD) (B) and Glutathione (GSH) (C).

of inflammatory parameters IL-1 β , IL-6 and TNF- α in mouse tissues. *In vitro* studies have similarly showed that ursolic acid significantly reduced the levels of inflammatory parameters IL-1 β , IL-6, IL-8 and TNF- α . These findings collectively support the notion that ursolic acid significantly inhibits inflammatory processes. In addition, it is plausible to assert that cells and animals experiencing inflammatory responses may benefit more from ursolic acid compared to healthy states. This observation might also be attributed to the frequent inclusion of ursolic acid in studies aimed at preventing and treating inflammatory diseases. In addition, the high consistency of results from animal and cellular studies further supports the anti-inflammatory activity of ursolic acid.

Ursolic	acid treat lesions (a	nimal studies)		Ursolic acid	treat lesions (<i>in</i>	vitro)
Dependent variable	Meta-regres:	sion parameter	(p-value)	Dependent variable	Meta-regressio (p-va	
	Dosage (mg/kg)	Duration (d)	Intervention		Dosage (µM)	Duration (h)
IL-1β	0.026	0.788	0.342	IL-1β	0.760	<0.0001
MDA	0.462	0.616	0.662	IL-6	0.169	0.295
TNF-α	0.857	0.339	0.637	IL-8	0.004	0.094
SOD	0.583	0.002	0.265	TNF-a	0.945	0.395

TABLE 1 The summary of the meta-regression analysis.

Abbreviations: IL-1 β , interleukin-1beta; MDA, malondialdehyde; TNF- α , tumor necrosis factor-alpha; SOD, superoxide dismutase; IL-6, interleukin-6; IL-8, interleukin-8.

TABLE 2 The summary of the sub-group analysis.

		_		Random e	ffects model		Test of heterog	leneity		ogroup erences
			n	Random effect	95% CI	<i>p</i> -value	Heterogeneity <i>I</i> ²	<i>p</i> -value	Q	<i>p</i> -value
Ursolic a	acid treat le	esions (animal studies)								
IL-1β	All trials	_	69	-4.07	[-5.59; -2.54]	< 0.0001	79 (%)	< 0.01	_	—
	Dosage	Low (<25 mg/kg)	34	-5.91	[-8.17; -3.65]	< 0.0001	68	0.01	12.05	0.002
		Middle (25-50 mg/kg)	26	-3.24	[-5.46; -1.02]	0.0043	77	< 0.01		
		High (>50 mg/kg)	9	-1.49	[-2.65; -0.33]	0.0116	0	0.51		
SOD	All trials	_	70	3.62	[1.97; 5.26]	< 0.0001	86	< 0.01	_	_
	Duration	Short (≤14 days)	12	5.24	[2.32; 8.15]	0.0004	49	0.16	1.28	0.26
		Long (>14 days)	58	3.24	[1.40; 5.09]	0.0006	86	< 0.01		
Ursolic a	acid treat le	esions (<i>in vitro</i>)								
IL-1β	All trials	_	39	-5.89	[-8.24; -3.54]	< 0.0001	60	< 0.01		
	Duration	Short (<20 h)	12	-1.85	[-3.23; -0.48]	0.008	45	0.14	18.56	< 0.0001
		Middle (20-40 h)	18	-6.94	[-9.43; -4.45]	< 0.0001	0	0.56		
		Long (>40 h)	9	-10.28	[-15.80; -4.76]	< 0.0001	0	0.88		
IL-8	All trials	_	42	-6.43	[-8.91; -3.94]	< 0.0001	53	< 0.01	_	_
	Dosage	Low (<10 µM)	15	-4.26	[-7.23; -1.29]	0.0049	48	0.10	6.09	0.048
		Middle (10–19 μM)	6	-5.78	[-9.67; -1.88]	0.0036	0	0.79		
		High (>19 µM)	21	-14.00	[-21.15; -6.86]	0.0001	38	0.14		

Abbreviations: IL-1β, interleukin-1beta; SOD, superoxide dismutase; IL-8, interleukin-8.

Antioxidant defense systems exist in most organisms, effectively scavenging free radicals and ROS. The redox dynamic balance is determined by the balance between the production of free radicals and ROS and their elimination by various antioxidants. Key enzymatic antioxidants in animals include SOD, GSH, GPx, and CAT (Fang et al., 2002). When there is an increased production of oxygen radicals or oxidizing substances in the body beyond the antioxidant defense mechanism of the cells, it results in cellular oxidative stress (Sarapultsev et al., 2015). MDA a byproduct of lipid peroxidation, serves as an indicator of cellular damage and a biomarker for oxidative stress severity (Tangvarasittichai, 2015). Several natural extracts, including vitamin C, vitamin E, flavonoids and polyphenols have demonstrated their ability to bolster the body's innate defense system and maintain redox homeostasis (Rubió et al., 2013). Our results showed that ursolic acid could significantly elevate SOD and GSH levels, while significantly reducing MDA levels in animal tissues. The results of *in vitro* studies shown that ursolic acid significantly increased the level of GSH and decreased the level of MDA. Hence, it is plausible to consider ursolic acid as a non-enzymatic antioxidant capable of fortifying cellular and organismal antioxidant defenses, thereby mitigating oxidative stress.

Interestingly, a previous study showed that ursolic acid increased IL-1 β levels in healthy mice in a concentration- and

	, y					
Parameter			Eg	ger's test		
	Ursolic a	acid (<i>in vitro</i>)		eat lesions (animal udies)	Ursolic acid trea	at lesions (<i>in vitro</i>)
		<i>p</i> -value		<i>p</i> -value		<i>p</i> -value
IL-1β	7.83	0.080	-6.85	<0.0001	-13.5	<0.0001
IL-6	0.19	0.869	-8.25	0.0004	-7.45	<0.0001
MDA			-5.79	< 0.0001	-2.93	0.022
SOD			10.74	< 0.0001	0.28	0.789
TNF-α			-6.76	< 0.0001	-4.62	0.0003
GSH			13.84	0.0008	2.95	0.098
GPx	_		_	_	-0.54	0.604
CAT	_	_	_	_	1.06	0.326
IL-10	_	_	_	_	120.58	0.005
IL-8	_	_	_	_	-70.81	<0.0001

TABLE 3 The summary of Egger's tests.

Abbreviations: IL-1β, interleukin-1beta; IL-6, interleukin-6; MDA, malondialdehyde; SOD, su-peroxide dismutase; TNF-α, tumor necrosis factor-alpha; GPx, glutathione peroxidase; CAT, catalase; IL-10, interleukin-10; GSH, glutathione; IL-8, interleukin-8.

time-dependent manner (Ikeda et al., 2007a). A high dosage of ursolic acid was associated with increased IL-1ß production in healthy mice (Ikeda et al., 2007b). Notably, the impact of ursolic acid on IL-1ß appeared to show opposite results in healthy versus diseased mice. While the exact reason for this discrepancy remains unclear, the aforementioned study suggests that the dose and duration of ursolic acid treatment could be decisive factors in its effects. Therefore, through regression analysis and subgroup analysis, we explored whether these two factors influence the effect of ursolic acid treatment and attempted to identify the source of heterogeneity. Ultimately, we identified dosage as a crucial factor affecting ursolic acid's ability to reduce IL-1 levels in animals. Lower doses (< 25 mg/kg) yielded a more potent therapeutic effect, whereas no therapeutic effect was found in the high-dosage group (>50 mg/kg). However, high heterogeneity remained in the low and intermediate dose groups, indicating the existence of other factors that may modulate ursolic acid's anti-inflammatory effects. In conclusion, ursolic acid possesses a robust anti-inflammatory effect, with lower doses being more efficacy, suggesting that ursolic acid has a complex mechanism of action and that pro-inflammatory effects may arise at higher doses.

In an investigation into the *in vitro* study, duration significantly affected IL-1 β levels, with longer durations (> 40 h) being able to reduce IL-1 β levels more substantially. Notably, we did not observe heterogeneity in any of the three subgroups, suggesting that varying durations may be the primary source of heterogeneity. Consequently, it appears that a longer duration is a critical factor contributing to the anti-inflammatory effects of ursolic acid *in vitro*. Interestingly, we also noted inconsistencies between factors affecting *in vivo* and *in vitro* studies. These disparities may be attributed to factors such as the bioavailability of ursolic acid, which could help elucidate these differences. In our *in vitro* investigations, we observed that dose was the main factor influencing the effect of ursolic acid on IL-8 production, where high doses (> 19 μ M) were able to produce greater therapeutic effects, and the low heterogeneity in the three subgroups suggests that different doses were a source of heterogeneity across these studies. Additionally, our observations indicated that ursolic acid significantly reduces SOD levels in animal studies, whereas no consistent effect was observed in *in vitro* studies. This inconsistency may be attributed to differences between *in vitro* and *in vivo* biological modeling systems.

The precise mechanisms underlying the effects of ursolic acid supplementation on markers of inflammation and oxidative stress remain elusive. However, we have suggested some potential mechanisms for ursolic acid and markers of inflammation and oxidative stress in our meta-analysis. Major molecular targets of Inflammatory diseases include pro-inflammatory cytokines and their receptors, nuclear factor kappa B (NF-KB), c-Jun-N-terminal kinases (JNK) and mitogen-activated protein kinases (MAPK) (Gautam and Jachak, 2009). Ursolic acid can suppress NF-KB activation by inhibiting IkB kinase and p65 phosphorylation (Shishodia et al., 2003). Notably, NF-κB regulates the expression of genes associated with proinflammatory cytokines (Sun, 2017; Yu et al., 2020). Thus, the anti-inflammatory effect of ursolic acid may be through the inhibition of NF- κ B to reduce inflammatory markers. Another pathway may involve ursolic acid exerting its anti-inflammatory effects by inhibiting the MAPK signaling pathway (Ma et al., 2014). Regarding its antioxidant function, ursolic acid may operate by scavenging free radicals (Shih et al., 2004; Li et al., 2018b). In addition, ursolic acid has been shown to inhibit oxidative stress through the liver kinase B1 (LKB1)-activated protein kinase (AMPK) signaling pathway (Yang et al., 2015).

	IL-1β Study	Experi Total Me	mental ean SD		Control Mean	SD	Standardised Mean Difference	SM	D 95%-CI	Weight (common)	Weight) (random)	P-value
	lkeda 2007(1) lkeda 2007(2) Leng 2016	3 10	65 35 065 350 7.60 5.55	3 3 3	30 30 54.40	4 4 5.54			4 [-0.09; 6.76	[] 18.5%	11.9% 38.3% 49.8%	
	Common effe		9			9		1.2 2.7	2 [-0.25; 2.69 8 [-1.07; 6.65		 100.0%	0.104 0.157
	Heterogeneity:	$l^2 = 66\%, \ t^2$	= 7.0283, p	= 0.05		-20) -10 0 10	20				
В	IL-6											
	Study	Experi Total Me	mental ean SD		Control Mean S	D	Standardised Mean Difference	SMD		Weight common) (Weight (random)	P-value
	Ikeda 2007(1) Ikeda 2007(2) TSAI 2008 Checker 2012	3 8. 10 13	27 0.81 12 1.81 .00 2.00 19 0.65	3 10	0.78 0.4 0.78 0.4 13.00 2.4 27.97 1.4	45 00		4.44 0.00	[-0.15; 6.22] [0.10; 8.78] [-0.88; 0.88] -36.80; -1.70]	6.8% 3.6% 89.4% 0.2%	29.7% 22.4% 45.4% 2.5%	
	Common effe Random effeo		19		19	-			[-0.50; 1.15] [-1.41; 4.25]	100.0% 	 100.0%	0.443 0.325
	Heterogeneity:	$l^2 = 74\%, \ t^2$	= 4.3844, p	< 0.01		-3	0-20-10 0 10 20 3	D				
C	SOD Study	Experi Total Me	imental		Control Mean	SD	Standardised Mear Difference	n SM	D 95%-CI	Weight	Weight) (random)	P-value
							Dimerence					r-value
	TSAI 2008 Samivel 2020		.36 0.22 0.34 0.55	10 6	9.06 17.25	0.17 1.27	[6 [0.45; 2.4 52 [-9.85; -3.		52.1% 47.9%	
	Common effe Random effe Heterogeneity:	cts model	16 ² = 30.2324,	p < 0.01	16	_			9 [-0.18; 1.7 36 [-10.17; 5.4		 100.0%	0.109 0.553
D	GSH Study	Experi			Control		Standardised Mear	.		Weight	Weight	
		Total Me	an SD	otal	Mean	SD	Difference		0 95%-CI		(random)	P-value
	TSAI 2008		ean SD		Mean	SD	Difference	SMI		(common)	. ,	P-value
		10 85	ean SD .00 3.00 .37 2.69	10 6	Mean 83.00 33.04	SD 2.00 2.79	Difference	SMI 	5 [-0.16; 1.66 56 [-1.73; 0.60	(common) 61.9% 38.1%	53.9% 66.1%	
	TSAI 2008 Samivel 2020 Common effe Random effec	10 85 6 31 ct model cts model	.00 3.00 .37 2.69 16	10 6	83.00	2.00 2.79		0.7 -0.5 0.2 0.1	5 [-0.16; 1.66	(common) 61.9% 38.1% 100.0%	53.9%	P-value 0.495 0.824
	TSAI 2008 Samivel 2020 Common effe Random effec Heterogeneity: /	$ \begin{array}{ccc} 10 & 85 \\ 6 & 31 \end{array} $ ct model ts model $ ^{2} = 67\%, \ ^{2} $.00 3.00 .37 2.69 16 = 0.5778, <i>p</i>	10 6 = 0.08	83.00 33.04 16	2.00 2.79	Difference	0.7 -0.5 0.2 0.1	5 [-0.16; 1.66 56 [-1.73; 0.60 5 [-0.47; 0.97	(common) 61.9% 38.1% 100.0%	53.9% 46.1%	0.495
	TSAI 2008 Samivel 2020 Common effe Random effec	$ \begin{array}{ccc} 10 & 85 \\ 6 & 31 \end{array} $ ct model ts model $ ^{2} = 67\%, \ ^{2} $.00 3.00 .37 2.69 16 = 0.5778, <i>p</i>	10 6 = 0.08	83.00 33.04	2.00 2.79		0.7 -0.5 0.2 0.1	5 [-0.16; 1.66 56 [-1.73; 0.60 5 [-0.47; 0.97	(common) 61.9% 38.1% 100.0% Weight	53.9% 46.1%	0.495 0.824
	TSAI 2008 Samivel 2020 Common effe Random effec Heterogeneity: / GPx	10 85 6 31 ct model :ts model ¹² = 67%, <i>t</i> Experi Total Me 10 73	.00 3.00 .37 2.69 16 = 0.5778, <i>p</i>	10 6 = 0.08	83.00 33.04 16 Control	2.00 2.79 SD 3.00	-1.5 -1 -0.5 0 0.5	SMI 0.7 0.2 0.1 1.5 n SMD 1.85	5 [-0.16; 1.66 56 [-1.73; 0.60 5 [-0.47; 0.97 5 [-1.14; 1.43	(common) 61.9% 38.1% 100.0% Weight (common 86.7%	53.9% 46.1% 100.0% Weight	0.495 0.824
	TSAI 2008 Samivel 2020 Common effe Random effec Heterogeneity: / GPx Study TSAI 2008 Samivel 2020 Common effe Random effe	10 85 6 31. ct model ts model $i^2 = 67\%, t^2$ Experi Total Me 10 73 6 9. ect model cts model	.00 3.00 .37 2.69 16 = 0.5778, <i>p</i> mental ean SD 0.07 3.22 .79 0.81 16	10 6 = 0.08 Total 10 6	83.00 33.04 16 Control Mean 67.07	2.00 2.79 SD 3.00	-1.5 -1 -0.5 0 0.5	SMI 0.7 0.7 0.2 0.1 1.5 N SMD 1.85 -5.24 0.91	5 [-0.16; 1.66 6 [-1.73; 0.60 5 [-0.47; 0.97 5 [-1.14; 1.43 95%-Cl [0.76; 2.93]	(common) 61.9% 38.1% 100.0% 100.0% 86.7% 13.3%	53.9% 46.1% 100.0% Weight) (random) 51.7%	0.495 0.824
E	TSAI 2008 Samivel 2020 Common effe Random effec Heterogeneity: / GPx Study TSAI 2008 Samivel 2020 Common effec Random effec Heterogeneity:	10 85 6 31. ct model ts model $i^2 = 67\%, t^2$ Experi Total Me 10 73 6 9. ect model cts model	.00 3.00 .37 2.69 16 = 0.5778, <i>p</i> mental ean SD 0.07 3.22 .79 0.81 16	10 6 = 0.08 Total 10 6	83.00 33.04 16 Control Mean 67.07 15.98	2.00 2.79 SD 3.00	-1.5 -1 -0.5 0 0.5	SMI 0.7 0.7 0.2 0.1 1.5 N SMD 1.85 -5.24 0.91	5 [-0.16; 1.66 6 [-1.73; 0.60 5 [-0.47; 0.97 5 [-1.14; 1.43 95%-Cl [0.76; 2.93] [-8.01; -2.48 [-0.10; 1.91]	(common) 61.9% 38.1% 100.0% 100.0% 86.7% 13.3%	53.9% 46.1% 100.0% Weight) (random) 51.7% 48.3%	0.495 0.824 P-value 0.078
E	TSAI 2008 Samivel 2020 Common effe Random effec Heterogeneity: / GPx Study TSAI 2008 Samivel 2020 Common effe Random effe	10 85 6 31 ct model its model $i^2 = 67\%, f^2$ Experi Total Mo 10 73 6 9. ct model cts model $i^2 = 95\%, f^2$.00 3.00 .37 2.69 16 = 0.5778, <i>p</i> mental ean SD 0.07 3.22 .79 0.81 16 2 = 23.9908, imental	$10 \\ 6$ $= 0.08$ $Total$ $10 \\ 6$ $p < 0.01$	83.00 33.04 16 Control Mean 67.07 15.98	2.00 2.79 SD 3.00	-1.5 -1 -0.5 0 0.5	SMI 0.7 -0.5 0.2 0.1 1.5 -5.24 0.91 -1.58 5	5 [-0.16; 1.66 6 [-1.73; 0.60 5 [-0.47; 0.97 5 [-1.14; 1.43 95%-Cl [0.76; 2.93] [-8.01; -2.48 [-0.10; 1.91]	(common) 61.9% 38.1% 100.0% Weight 13.3% 100.0% Weight	53.9% 46.1% 100.0% Weight) (random) 51.7% 48.3%	0.495 0.824 P-value 0.078 0.656
E	TSAI 2008 Samivel 2020 Common effe Random effec Heterogeneity: / GPx Study TSAI 2008 Samivel 2020 Common effe Random effe Heterogeneity: CAT	10 85 6 31 ct model ts model $t^2 = 67\%, t^2$ Experi Total Model $t^2 = 95\%, t^2$ Experi Total Model 10 2.	.00 3.00 .37 2.69 16 = 0.5778, <i>p</i> mental ean SD 0.07 3.22 .79 0.81 16 2 = 23.9908, imental	$10 \\ 6$ $= 0.08$ $Total$ $10 \\ 6$ $p < 0.01$	83.00 33.04 16 Control Mean 67.07 15.98 16 Control	2.00 2.79 SD 3.00 1.31 SD 0.20	-1.5 -1 -0.5 0 0.5 Standardised Mea	SMI 0.7 -0.5 0.2 0.1 1.5 -5.24 0.91 -1.58 5 -0.83	5 [-0.16; 1.66 6 [-1.73; 0.60 5 [-0.47; 0.97 5 [-1.14; 1.43 95%-Cl [0.76; 2.93] [-8.01; -2.48 [-0.10; 1.91] [-8.52; 5.37]	(common) 61.9% 38.1% 100.0% Weight 13.3% 100.0% Weight	53.9% 46.1% 100.0% Weight) (random) 51.7% 48.3% 100.0% Weight	0.495 0.824 P-value 0.078 0.656

FIGURE 6

Characteristic of *in vitro* studies regarding the effect of ursolic acid on inflammatory and antioxidant markers. Interleukin-1beta (IL-1β) (**A**), Interleukin-6 (IL-6) (**B**), Superoxide dismutase (SOD) (**C**), Glutathione (GSH) (**D**), Glutathione peroxidase (GPx) (**E**) and Catalase (CAT) (**F**).

Ursolic acid demonstrates the potential to reduce the marker levels of inflammation and oxidative stress, making it a valuable candidate for both preventive measures and adjunctive treatments in cases of chronic inflammation and oxidative stress-related damage. Given that chronic inflammation and oxidative stress tend to escalate with age and are implicated in the onset of numerous age-related diseases, the versatility of ursolic acid makes it particularly promising, especially for elderly

Α IL-1β																	
	Study	Expe Total N	rimenta Aean		Co otal M	ean	SD	Sta	ndardised Differen			SMD	95%-0	CI (Weight common)	Weight (random)	P-val
	Manu 2008(1) Manu 2008(2) Manu 2008(3)	3 6	57.90 1	1.80	3 9	8.90 3	2.70 2.70 2.70 -	-				-10.78	[-17.03; - [-20.70; - [-23.76; -	0.86]	2.1% 1.4% 1.1%	5.6% 4.2% 3.4%	
	Checker 2012(8) Jang 2014(1)	3 42	28.30 7 0.62 0	7.01).18	3 51 4 3	2.55	7.02 0.33	-				-9.58 -8.53	[-18.43; - [-14.40; -	0.74] 2.66]	1.8% 4.0%	5.0% 8.3%	
	Jang 2014(2) Jang 2014(3)	4 (0.35 0	0.13	4 3	.23 (0.33 0.33	_				-9.97	[-15.75; - [-16.79; -	3.16]	3.4% 3.0%	7.5% 7.0%	
	Leng 2016(1) Wang 2017(1)	3 3	1.50 1	2.67	3 4	5.73	8.31 5.63					-1.16	[-11.14; - [-3.07; (0.76]	4.7%	8.9% 15.4%	
	Wang 2017(2) Jia 2021(3) Jia 2021(4)	3 15	51.46 19 30.10 1	9.42	3 27	5.73 ± 3.79 2 3.79 2			-				[-3.86; ([-8.98; - [-10.87; -	0.12]	28.7% 7.1% 4.9%	14.9% 10.6% 9.1%	
	Common effect r Random effects Heterogeneity: $l^2 =$	model	39	n < 0.01		39		_	•		_		[-4.56; - [-8.24; -		100.0% 	 100.0%	<0.00 <0.00
B ⊪-6	Heterogeneity. 7 -					0		-20	-10 0	10	20				10000 Ki 2000		
	Study		xperime I Mean	SD		Contro Mean		s	tandardise Differe			SMD	95%	-CI	Weight (common)	Weight (random)	P-va
	TSAI 2008 Manu 2008(1)	10 3	28.00 44.10	4.00 3.90	10 3	53.00 58.90			8			-4.70 -2.60	[-6.53; [-5.45;		18.1% 7.5%	9.9% 8.2%	
	Manu 2008(2) Manu 2008(3)	3 3	41.37 39.32	3.40 2.90	3 3	58.90 58.90	5.10		1			-3.23 -3.77	[-6.57;	0.11]	5.5% 4.3%	7.4% 6.7%	
	Checker 2012(2) Checker 2012(3)	3 3	104.68 82.31	1.21 2.40	3 3	110.2			-	ł		-1.28 -5.89	[-3.25;		15.6% 2.0%	9.7% 4.5%	
	Checker 2012(4) Checker 2012(5)	3 3	68.72 7.19	1.07 0.14	3 3	110.2			ہـ ہــــ			-9.55 -24.27	[-18.37;	-0.731	0.8%	2.3%	
	Checker 2012(6) Checker 2012(7)	3	15.53 8.00	1.83	3 3	56.62 90.00	0.96	_	;			-22.44	[-42.87;	-2.00]	0.1%	0.5%	
	Checker 2012(8) Jang 2014(1)	3	655.32 0.09		3	997.02				1		-6.82	[-13.21;	-0.421	1.5%	3.7%	
	Jang 2014(2)	4	0.06	0.02	4	0.43	0.04		+			10.16	[-17.10;	-3.23]	1.3%	3.3%	
	Jang 2014(3) Chen 2016(1)	3	0.03 329.76	3.82	4 3	0.43 449.00			4	-		-11.92 -9.43	[-20.01; [-18.15;	-0.72]	0.8%	2.7% 2.4%	
	Chen 2016(2) Chen 2016(3)	3 3	269.44 229.22	9.38	3 3	449.06 449.06	6 13.75			1	1	-14.15 -14.90	[-27.09; [-28.53;	-1.28]	0.4% 0.3%	1.2% 1.1%	
	Wang 2017(1) Wang 2017(2)	3 3	271.33 269.73	33.37	3 3	322.7 322.7	1 30.59					-1.28 -1.21	[-3.26;	0.70]	15.6% 16.2%	9.7% 9.7%	
	Jia 2021(3) Jia 2021(4)	3 3	273.79 227.18	34.95	3 3	463.1	1 46.60 1 46.60		4.4			-3.67 -4.84	[-7.36; [-9.52;	0.03]	4.5% 2.8%	6.8% 5.5%	
	Common effect r Random effects	model	73			73			; ; ;			-3.21 -4.64	[-3.99; [-6.14;	-2.43]	100.0%	 100.0%	<0.0
C IL-8	Heterogeneity: I ² =		= 5.0651,			Cor	ntrol				50						
-	Study	Tota	l Mean	n SD	Tot	al Mo	ean S	6D	Sta	Differ		ean SMD	95%	-CI (Weight common)		P-va
L	_ee 2008(1) _ee 2008(2)	3 3		2 47.12	3	782	2.12 2	7.49 7.49			1	-1.45	[-7.43	; 0.02]	14.7%	19.0% 14.7%	
L L	_ee 2008(3) _ee 2008(4)	3	507.8 507.8		3			7.49 7.49				-10.8	3 [-20.79	; -0.87	2.1%	4.8% 5.6%	
L	ee 2008(5) ee 2008(6)	3	498.74	4 51.05 0 51.05	3			7.49		- <u>14</u> -14		-5.5	[-10.77	; -0.26	7.4%	11.1%	
				6 35.34				7.49				-8.9	[-17.16			6.4%	
-	ee 2008(7)	3			3			7 49							0.8%		
L	_ee 2008(8) _ee 2008(9)	3 3	219.9 54.41	0 23.56 I 3.93	3	782	2.12 27	7.49		-		-29.5	7 [-56.47	; -2.67	0.8%	2.2% 0.8%	
	_ee 2008(8) _ee 2008(9) _ee 2008(10) _ee 2008(11)	3 3 3 3	219.9 54.41 9.07 4.53	0 23.56 3.93 35.34 15.71	3 3 3 3	782 782 782 782	2.12 21 2.12 21 2.12 21 2.12 21 2.12 21	7.49 7.49 7.49	=			-29.5 -19.4 -27.7	7 [-56.47 8 [-37.24 1 [-52.92	; -2.67 ; -1.72 ; -2.50	0.8% 0.3% 0.6% 0.3%	2.2% 0.8% 1.8% 0.9%	
	Lee 2008(8) Lee 2008(9) Lee 2008(10) Lee 2008(11) Lee 2008(12) Chun 2014(1)	3 3 3 3 3	219.90 54.41 9.07 4.53 4.46 285.75	0 23.56 3.93 35.34 15.71 23.70 8 23.03	3 3 3 3 3 3	78: 78: 78: 78: 78: 78: 45:	2.12 2.12 2.12 2.12 2.12 2.12 2.12 2.12 2.12 2.12 3.73 2.12	7.49 7.49 7.49 7.49 7.09				-29.5 -19.4 -27.7 -24.1 -5.33	7 [-56.47 8 [-37.24 1 [-52.92 8 [-46.19 3 [-10.43	, -2.67 , -1.72 , -2.50 , -2.17 , -0.23	0.8% 0.3% 0.6% 0.3% 0.4% 7.9%	2.2% 0.8% 1.8% 0.9% 1.2% 11.4%	
	Lee 2008(8) Lee 2008(9) Lee 2008(10) Lee 2008(11) Lee 2008(12) Chun 2014(1) Chun 2014(2) Common effect r	3 3 3 3 3 3 3 3 model	219.90 54.41 9.07 4.53 4.46 285.75	0 23.56 3.93 35.34 15.71 23.70	3 3 3 3 3	78: 78: 78: 78: 78: 78: 45:	2.12 2.12 2.12 2.12 2.12 2.12 2.12 2.12 2.12 2.12 2.12 2.12	7.49 7.49 7.49 7.49 7.09		-++-×		-29.5 -19.4 -27.7 -24.1 -5.33 -5.82 -5.82	7 [-56.47 8 [-37.24 1 [-52.92 8 [-46.19 3 [-10.43 2 [-11.35 0 [-5.53	; -2.67 ; -1.72 ; -2.50 ; -2.17 ; -0.23 ; -0.30	0.8% 0.3% 0.6% 0.3% 0.4% 7.9% 6.7%	2.2% 0.8% 1.8% 0.9% 1.2% 11.4% 10.5%	
	Lee 2008(8) Lee 2008(9) Lee 2008(10) Lee 2008(11) Lee 2008(12) Chun 2014(1) Chun 2014(2)	3 3 3 3 3 3 3 3 model model	219.90 54.41 9.07 4.53 4.46 285.70 255.90 42	0 23.56 3.93 35.34 15.71 23.70 8 23.03 8 27.09	3 3 3 3 3 3 3 3 3	78: 78: 78: 78: 78: 78: 45: 45:	2.12 2.12 2.12 2.12 2.12 2.12 2.12 2.12 2.12 2.12 3.73 2.12	7.49 7.49 7.49 7.49 7.09	-40	+	5 2	-29.5 -19.4 -27.7 -24.1 -5.33 -5.82	7 [-56.47 8 [-37.24 1 [-52.92 8 [-46.19 3 [-10.43 2 [-11.35	; -2.67 ; -1.72 ; -2.50 ; -2.17 ; -0.23 ; -0.30	0.8% 0.3% 0.6% 0.3% 0.4% 7.9% 6.7%	2.2% 0.8% 1.8% 0.9% 1.2% 11.4%	
	ee 2008(8) ee 2008(9) ee 2008(10) ee 2008(12) chun 2014(1) chun 2014(2) Common effect r Random effects i Heterogeneity: I ² =	3 3 3 3 model model 53%, 7 Ex	219.90 54.41 9.07 4.53 4.46 285.70 255.90 42	0 23.56 1 3.93 35.34 15.71 23.70 8 23.03 8 27.09 9, p < 0.0 11	3 3 3 3 3 3 3 3 1	78: 78: 78: 78: 78: 45: 45: 45: 45: 45: 45: 45:	2.12 21 2.12 21 2.12 22 2.12 21 2.12 21 2.12 21 3.73 21 3.73 21 3.73 21	7.49 7.49 7.49 7.49 7.09	Standar	-20 (-29.5 -19.4 -27.7 -24.1 -5.3 -5.8 -4.10 -6.4	7 [-56.47 8 [-37.24 1 [-52.92 8 [-46.19 3 [-10.43 2 [-11.35 0 [-5.53	-2.67 -1.72 -2.50 -2.17 -0.23 -0.30 -2.66] -3.94]	0.8% 0.3% 0.6% 0.3% 0.4% 7.9% 6.7%	2.2% 0.8% 1.8% 0.9% 1.2% 11.4% 10.5% 100.0%	<0.0
D TNF-a	ee 2008(8) ee 2008(9) ee 2008(10) ee 2008(11) ee 2008(12) Chun 2014(1) Chun 2014(2) Common effect s leterogeneity: I ² = study TSAI 2008	3 3 3 3 3 3 3 5 3 5 3 5 3 5 3 5 3 5 3 5	219.90 54.41 9.07 4.53 4.46 285.74 255.96 42 = 7.3325 42 5 6 6 7 7 7 8 7 1 1 1 1 1 1 1 1 1 1	0 23.56 3.93 35.34 15.71 23.70 8 23.03 8 27.09 9, p < 0.0 10 11 12 15 15 15 15 15 15 15 15 15 15	3 3 3 3 3 3 3 1 1 Total	78: 78: 78: 78: 78: 45: 45: 45: 42 Contro Mean 59.00	2.12 21 2.12 22 2.12 22 2.12 21 2.12 21 2.12 21 3.73 21 3.73 21 3.73 21 5 5 7 .00	7.49 7.49 7.49 7.49 7.09	Standar	-20 (-29.5 -19.4 -27.7 -24.11 -5.33 -5.82 -4.10 -6.43 20 40 SMD	7 [-5.6.47 8 [-37.24 1 [-52.92 8 [-46.19 3 [-10.43 2 [-11.35 0 [-5.53 3 [-8.91 95%	-2.67 -1.72 -2.50 -2.17 -0.23 -0.30 -2.66 -3.94 -CI	0.8% 0.3% 0.6% 0.3% 0.4% 7.9% 6.7% 100.0% 	2.2% 0.8% 1.8% 0.9% 1.2% 11.4% 10.5% 100.0% Weight (random) 11.6%	<0.00
D TNF-a	ee 2008(8) ee 2008(10) ee 2008(10) ee 2008(11) ee 2008(12) Chun 2014(2) Common effect r Random effects r leterogeneity: /² = Study TSAI 2008 Manu 2008(1) Manu 2008(2)	3 3 3 3 3 3 3 5 3 5 3 5 5 3 , t^2 Ex Total 10 3 3	219.94 54.41 9.07 4.53 4.46 285.77 255.94 42 = 7.3325 = 7.3325 = 7.3325 = 7.3325 = 38.00 23.86 23.30	0 23.56 3.93 35.34 15.71 23.70 8 23.03 8 27.09 9, p < 0.0 1.90 2.20	3 3 3 3 3 3 3 3 1 1 Total 10 3 3	78: 78: 78: 78: 45: 45: 45: 42 Contro Mean 59:00 28:20 28:20	2.12 21 2.12 22 2.12 21 2.12 21 2.12 21 2.12 21 2.12 21 3.73 21 3.73 21 3.73 21 5 5 7 .00 2.50	7.49 7.49 7.49 7.49 7.09	Standar	-20 (-29.5 -19.4 -27.7 -24.1 -5.3 -5.8 -6.44 -6.44 -0 -6.4 -0 -6.4 -0 -6.4 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0	7 [-56.47 8 [-37.24 1 [-52.92 8 [-46.19 3 [-10.43 2 [-11.35 9 [-5.53 8 [-8.91 95% [-5.29; [-3.70; [-3.80; [-3.80;	-2.67 ; -1.72 ; -2.50 ; -2.17 ; -0.23 ; -0.23 ; -0.30 ; -0.30 ; -3.94]	0.8% 0.3% 0.6% 0.3% 0.4% 7.9% 6.7% 100.0% Weight (common) 15.4% 8.2% 7.7%	2.2% 0.8% 1.8% 0.9% 1.2% 11.4% 10.5% 100.0% Weight (random) 11.6% 8.3%	<0.00
	ee 2008(8) ee 2008(10) ee 2008(10) ee 2008(11) ee 2008(12) Chun 2014(2) Common effect s leterogeneity: /² = Study TSAI 2008 Manu 2008(1) Manu 2008(2) Manu 2008(2) Manu 2008(2) Manu 2008(2)	3 3 3 3 3 3 3 model model 53%, 7 Ex Total 10 3 3 3 3 3	219.94 54.41 9.07 4.53 4.46 285.74 255.94 42 = 7.3325 5 6 6 7 7 8 8 9 1 1 1 1 1 1 1 1 1 1	0 23.56 3.93 35.34 15.71 23.70 8 23.03 8 27.09 9, p < 0.0 1.00 1.90 2.34	3 3 3 3 3 3 3 3 1 1 10 3 3 3 3 3	78: 78: 78: 78: 78: 45: 45: 45: 45: 42: 42 Contro Mean 59:00 28:20 28:20 28:20 449:36	2.12 21 2.12 22 2.12 22 2.12 22 2.12 22 2.12 22 3.73 23 3.73 23 3.73 23 5 5 7 .00 2.50 2.50 2.50 2.50 2.50 2.50	7.49 7.49 7.49 7.49 7.09	Standar	-20 (-29.5 -19.4 -27.7 -24.1 -5.3 -5.8; -4.11 -6.4; -6.4; -6.4; -0.40 -3.73 -1.56 -1.66 -2.00 -11.32	7 [-56.47 8 [-37.24 1 [-52.92 8 [-46.19 3 [-10.43 2 [-11.35 0 [-5.53 3 [-8.91 95% [-5.29; [-3.70; [-3.70; [-3.86; [-4.42; [-21.72]	-CI -2.18] -2.50 ; -2.50 ; -2.77 ; -0.23 ; -0.30 ; -2.66 ; -3.94] -2.66 ; -3.94] -2.68 ; -3.94] -2.58] 0.58] 0.54] 0.42] -0.92]	0.8% 0.3% 0.6% 0.3% 0.4% 7.9% 6.7% 100.0% Weight (common) 15.4% 8.2% 7.7% 6.4% 0.3%	2.2% 0.8% 1.8% 0.9% 1.2% 11.4% 10.5% 100.0% Weight (random) 11.6% 8.3% 8.0% 7.1% 0.6%	<0.00
	e.e 2008(8) .ee 2008(10) .ee 2008(10) .ee 2008(11) .ee 2008(12) .chun 2014(2) Common effects leterogeneily: / ² = Study TSAI 2008 Manu 2008(2) Manu 2008(2) Manu 2008(2) Manu 2008(2) Manu 2008(2) Manu 2008(2) Manu 2008(2) Manu 2012(8) Jang 2014(1) Jang 2014(2)	3 3 3 3 3 3 5 5 3%, 7 Ex Total 10 3 3 3 3	219.94 54.41 9.07 4.53 4.46 285.74 255.94 42 = 7.3325 5 6 6 7 8 8 8 9 6 1 1 1 1 1 1 1 1 1 1	0 23.56 3.93 35.34 15.71 23.70 8 23.03 8 27.09 9, p < 0.0 1.00 1.90 2.20 1.86	3 3 3 3 3 3 3 3 3 1 Total 10 3 3 3	78: 78: 78: 78: 78: 78: 45: 45: 42 42 62 60 78 78 78 78 78 78 78 78	2.12 21 2.12 21 2.12 21 2.12 21 2.12 21 2.12 21 3.73 21 3.73 21 3.73 21 SD 7.00 2.50 2.50 2.50	7.49 7.49 7.49 7.49 7.09	Standar	-20 (-29.5 -19.4 -27.7 -24.1 -5.33 -5.83 -4.10 -6.43 -0.40 SMD -3.73 -1.56 -1.66 -2.00	7 [-56.47 8 [-37.24 1 [-52.92 8 [-46.19 3 [-10.43 2 [-11.35 2 [-11.35 3 [-8.91] [-5.53 8 [-8.91] [-5.29; [-3.70; [-3.86; [-4.22; [-4.95; [-4.95;	-2.67; -1.72; -2.50; -2.50; -2.17; -0.23; -0.30; -2.66]; -3.94] -3.94] -2.18] 0.58] 0.54] 0.54] 0.42] -0.92] -0.42]	0.8% 0.3% 0.6% 0.3% 0.4% 7.9% 6.7% 100.0% Weight (common) 15.4% 8.2% 7.7% 6.4%	2.2% 0.8% 1.8% 0.9% 1.2% 11.4% 10.5% 100.0% Weight (random) 11.6% 8.3% 8.0% 7.1% 0.8% 7.1%	<0.00
D TNF-a	ee 2008(8) eee 2008(9) eee 2008(10) eee 2008(11) eee 2008(12) chun 2014(2) common effect r andom effects r study TSAI 2008 Manu 2008(2) Manu 2008(3) Checker 2012(8) Jang 2014(2) Jang 2014(3)	3 3 3 3 3 3 3 3 53%, 7 Ex Total 10 3 3 3 4 4 4 4	219.94 54.41 9.07 4.53 4.46 285.71 255.94 42 = 7.3325 = 7	0 23.56 3.03 35.34 15.71 23.70 8 23.03 8 27.09 9, p < 0.0 1.90 2.20 1.90 2.20 1.90 2.34 0.01 0.02	3 3 3 3 3 3 3 3 3 1 1 10 3 3 3 3 4 4 4 4	78: 78: 78: 78: 78: 78: 45: 45: 45: 42: 42: 60: 82: 82: 82: 82: 82: 82: 82: 82: 82: 82	2.12 2: 2.12 2: 2.12 2: 2.12 2: 2.12 2: 3.73 2: 3.73 2: 3.73 2: 50 50 50 50 50 50 50 50 50 50 50 50 50	7.49 7.49 7.49 7.49 7.09	Standar	-20 (-29.5 -19.4 -27.7 -24.1 -5.3 -5.8; -4.11 -5.8; -6.4; -6.4; -0.40 -0.40 -3.73 -1.56 -1.66 -2.00 -11.32 -2.68 -3.68 -3.68 -3.73 -4.77	7 [-56.47 8 [-37.24 1 [-52.92 8 [-46.16 3 [-10.32 2 [-11.35 9 [-5.53 3 [-8.91 95% [-5.29; [-3.70; [-3.70; [-3.86; [-4.42; [-4.72; [-4.95; [-6.77; [-8.24; [-8.24; [-8.77; [-8.24; [-8.24];	-CI -2.18] -2.50 ; -2.50 ; -2.50 ; -2.17 ; -0.23 ; -0.30 ; -2.66 ; -3.94 -2.18 0.58 0.58 0.58 0.58 0.42 -0.92 -0.92 -0.92 -0.92 -0.92 -1.29	0.8% 0.3% 0.6% 0.3% 0.4% 7.9% 6.7% 100.0% 	2.2% 0.8% 1.8% 1.2% 11.4% 10.5% 100.0% Weight (random) 11.6% 8.3% 8.3% 8.3% 5.5% 4.2%	<0.00
	e.e 2008(8) .e.e 2008(10) .e.e 2008(10) .e.e 2008(11) .e.e 2008(12) .blun 2014(2) Common effect r study TSAI 2008 Manu 2008(2) Manu 2008(3) Checker 2012(8) Jang 2014(2) Jang 2014(2) Jang 2014(3) Chen 2016(1) Chen 2016(2)	3 3 3 3 3 3 3 3 53%, 7 Ex Total 10 3 3 3 4 4 4 3 3 3	219.9(54.41 9.07 4.53 4.66 285.7(255.9(42 = 7.3325 = 7.335 = 7.355 = 7.555 = 7.5555 = 7.55555 = 7.55555 = 7.5555 = 7.555555 = 7.55555 = 7.555	0 23.56 1 3.93 35.34 15.71 23.70 8 23.03 8 27.09 9, p < 0.0 1.90 2.20 1.86 3.00 1.90 2.20 1.86 0.02 0.01 4.02 2.68	3 3 3 3 3 3 3 3 3 1 1 10 3 3 3 4 4 4 3 3 3	78; 78; 78; 78; 78; 45; 45; 45; 45; 45; 42; 42; 60,00 28,20 28,20 28,20 28,20 28,20 28,20 28,20 0,19 0,19 0,19 0,19 0,19 0,19	2.12 2: 2.12 2: 2.12 2: 2.12 2: 2.12 2: 2.12 2: 2.12 2: 3.73 2: 3.73 2: 3.73 2: 7.00 2.50 2.50 2.50 0.4 0.04 0.04 0.04 13.41 13.41	7.49 7.49 7.49 7.49 7.09	Standar	-20 (-29.5 -19.4 -27.7 -24.1 -5.33 -5.83 -5.83 -5.83 -6.41 -6.44 -6.44 -0 -0 -0 -0 -11.32 -2.08 -3.855 -4.77 -9.72 -14.82	7 [-56.47 8 [-37.24] 8 [-37.24] 9 [-46.16] 9 [-5.29] 9 [-5.53] 9 [-5.53] 9 [-5.53] 9 [-5.29] [-3.70] [-3.70] [-3.86] [-3.70] [-3.86] [-4.42] [-21.72] [-4.42] [-8.73] [-8.74] [-8.74] [-8.74] [-8.74] [-8.76] [-8.74] [-8.76] [-7.76]	-CI -2.66 -2.18] -2.50 -2.66 -3.94] -2.18] 0.58] 0.58] 0.54] 0.54] 0.54] 0.54] 0.54] 0.54] 0.54] 0.54] 0.54] 0.54] 0.54] 0.54] 0.54] 0.54]	0.8% 0.8% 0.6% 0.3% 0.4% 7.9% 6.7% 100.0% 	2.2% 0.8% 1.8% 1.2% 11.4% 10.5% weight (random) 11.6% 8.3% 8.3% 8.3% 8.0% 7.1% 0.8% 0.8% 0.3%	<0.00
	e.e 2008(8) .e.e 2008(10) .e.e 2008(10) .e.e 2008(11) .e.e 2008(12) .bhun 2014(2) Common effect r study TSAI 2008 Manu 2008(2) Manu 2008(3) Checker 2012(8) Jang 2014(2) Jang 2014(2) Jang 2014(2) Jang 2014(2) Chen 2016(2) Chen 2016(2) Ch	3 3 3 3 3 3 3 3 3 3 3 5 53%, \hat{f} Ex Total 10 3 3 3 3 4 4 4 4 4 3 3 3 3 3	219.9% 54.41 9.07 4.53 4.46 285.7/ 255.9% 42 = 7.3325 9% 9% 9% 9% 9% 9% 9% 9% 9% 9% 9% 9% 9%	0 23.56 1 3.93 35.34 15.71 23.70 8 23.03 8 27.09 9, p < 0.0 1.90 2.20 1.90 2.30 1.90 2.20 0.01 1.86 2.34 0.01 0.02 0.02 0.02 0.02 2.68 9.38 9.38 9.38 9.7 9.7 9.7 9.7 9.7 9.7 9.7 9.7	3 3 3 3 3 3 3 3 3 3 4 4 4 3 3 3 4 4 4 3 3 3 3 3	78: 78: 78: 78: 78: 78: 45: 45: 45: 42 Contro Mean 59:00 28:20 28:20 28:20 28:20 28:20 0.19 0.19 0.19 0.19 0.19 450:40 450:40 450:40	2.12 2: 2.12 2: 2.12 2: 2.12 2: 2.12 2: 2.12 2: 3.73 2: 3.73 2: 3.73 2: 7.00 2.50 0.4 0.04 0.04 0.04 0.04 0.04 1.13.41 1.3.41 9.82	7.49 7.49 7.49 7.49 7.09	Standar	-20 (-29.5,	7 [-56.47 8 [-37.24] 8 [-37.24] 8 [-46.19 8 [-46.19 8 [-46.19 8 [-46.19 9 [-5.33 2 [-11.35 9 [-5.53 8 [-8.91 9 [-5.53 8 [-8.91 9 [-3.70] [-3.70] [-3.76] [-3.76] [-3.76] [-3.78] [-4.42] [-4.72] [-4.72] [-4.72] [-8.24] [-8.24] [-8.24] [-28.37] [-28.37] [-28.37] [-28.37] [-28.37] [-28.19] [-28.23] [-28.19] [-28.23] [-28.24] [-28.24] [-28.27] [-28.27] [-28.24] [-28.24] [-28.24] [-28.24] [-28.24] [-28.24] [-28.24] [-28.24] [-28.24] [-3.76]	-Cl -2.67 ; -2.50 ; -2.17 ; -0.23 ; -0.30 -2.66 (-3.94) -2.66 (-3.94) -2.66 (-3.94) -2.66 (-3.94) -2.66 (-3.94) -2.66 (-3.94) -2.66 (-3.94) -2.66 (-3.94) -2.60 (-3.94) -2	0.3% 0.3% 0.6% 0.3% 0.4% 0.4% 7.9% 6.7% 100.0% Weight (common) 15.4% 8.2% 7.7% 6.4% 0.3% 7.3% 7.3% 7.3% 6.4% 0.3% 0.2% 4.9%	2.2% 0.8% 1.8% 0.9% 1.2% 11.4% 10.5% 100.0% 100.0% 100.0% 11.6% 8.0% 7.1% 0.6% 7.1% 0.6% 7.7% 0.6% 0.6% 0.3% 0.3% 6.0%	<0.00
	e.e 2008(8) .e.e 2008(10) .e.e 2008(10) .e.e 2008(11) .e.e 2008(12) .bhun 2014(2) Common effect r andom effects r study TSAI 2008 Manu 2008(2) Manu 2008(3) Checker 2012(8) Jang 2014(2) Jang 2014(2)	3 3 3 3 3 3 3 3 3 3 3 5 3%, f Total 10 3 3 3 3 4 4 4 4 4 3 3 3 3 3 3 3 3 3 3	219.9% 54.44 9.07 4.53 4.46 285.7% 255.9% 42 42 42 42 42 42 42 42 	0 23.56 3.93 35.34 15.71 23.70 23.70 23.70 8 23.03 23.70 9, $\rho < 0.0$ tal SD 3.00 1.90 2.20 3.00 1.90 2.20 0.01 1.86 2.34 0.01 0.02 0.01 1.86 8.21 0.02 0.01 1.90 0.02 0.02 0.03 8.33 0.01 1.90 0.02 0.02 0.02 0.03 0.02 0.03 0.02 0.03 0.02 0.03 0.03 0.02 0.03 0.02 0.03 0.02 0.03 0.02 0.03 0.02 0.03 0.02 0.03 0.02 0.03 0.02 0.03 0.02 0.03 0.02 0.03 0.02 0.03 0.02 0.03 0.02 0.03 0.02 0.02 0.03 0.02 0.02 0.03 0.02 0.02 0.03 0.02 0.02 0.02 0.02 0.03 0.02 0.03 0.02 0.03 0.02 0.03 0.02 0.03 0.02 0.03 0.02 0.03 0.02 0.03 0.02 0.03 0.02 0.03 0.02 0.03 0.03 0.02 0.03 0.03 0.03 0.02 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.04 0.04 0.02 0.03	3 3 3 3 3 3 3 3 3 3 3 4 4 4 3 3 3 3 3 3	78: 78: 78: 78: 78: 78: 78: 78: 78: 78:	2.12 2: 2.12 2: 2.12 2: 2.12 2: 2.12 2: 2.12 2: 3.73 2: 3.73 2: 3.73 2: 3.73 2: 5.50 2.50 2.50 2.50 2.50 2.50 0.04 0.04 13.41 13.41 13.41 13.41 13.41	7.49 7.49 7.49 7.49 7.09	Standar	-20 (-29.5, 2 -19.4, -27.7, -24.1, -19.4, -27.7, -24.1, -5.3, -5.8, -5.	7 [-56.47 8 [-37.24] 8 [-37.24] 8 [-46.19 8 [-46.19 8 [-10.43] 2 [-11.35 9 [-5.53 8 [-8.91] 9 [-5.53 8 [-8.91] 9 [-5.29; [-3.70; [-3.70; [-3.70; [-3.86; [-4.42; [-21.72; [-4.45; [-1.87; [-29.12; [-4.44; [-1.84] [-1.84] [-1.84] [-1.84]	-Cl -Cl -Cl -Cl -Cl -Cl -Cl -Cl -Cl -Cl	0.3% 0.3% 0.6% 0.3% 0.4% 0.4% 0.4% 0.4% 17.9% 6.7% 100.0% 15.4% 8.2% 7.7% 6.4% 0.3% 6.4% 0.3% 0.3% 5.4% 0.2% 4.4% 0.2% 6.3% 0.2% 6.3%	2.2% 0.8% 1.8% 0.9% 1.2% 11.4% 10.5% 100.0% 100.0% 100.0% 11.6% 8.3% 8.0% 8.0% 8.0% 8.0% 5.5% 4.2% 0.8% 0.3% 6.0% 6.0% 6.0% 6.0% 6.0% 6.1%	<0.00
	e.e 2008(8) .e.e 2008(10) .e.e 2008(10) .e.e 2008(11) .e.e 2008(12) .bhun 2014(2) Common effects i study TSAI 2008 Manu 2008(2) Manu 2008(3) Checker 2012(8) Jang 2014(2) Jang 2014(2) J	3 3 3 3 3 3 3 3 3 3 3 5 53%, 7 Ex Total 10 3 3 3 3 4 4 4 3 3 3 3 3 3 3 3 3 3 3 3	219.90 54.41 9.07 4.53 4.46 285.77 255.91 42 = 7.3325 9 = 7.5325 9 = 7.3325 9 = 7.5325 9 = 7.5325 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	0 23.56 3.57 3.5.24 23.70 0 8 23.03 8 27.09 9, p < 0.0 1.86 5D 1.90 2.20 1.90 2.23 0.01 1.90 2.23 0.01 1.90 2.23 0.01 1.90 2.34 0.01 1.90 2.34 0.01 0.02 0.03 0.04 1.92 1.93 1.92 1.93 1.92 1.93 1.92 1.93 1.92 1.93 1.92 1.93 1.93 1.93 1.93 1.93 1.93 1.93 1.93 1.93 1.93 1.94 1.93	3 3 3 3 3 3 3 3 3 3 3 3 4 4 4 3 3 3 3 3	78: 78: 78: 78: 78: 78: 78: 78: 78: 78:	2.12 2: 2.12 2: 2.12 2: 2.12 2: 2.12 2: 2.12 2: 3.73 2: 3.73 2: 3.73 2: 3.73 2: 3.73 2: 5.50 2.50 2.50 2.50 2.50 2.50 2.50 14.04 0.04 0.04 13.41 13.41 13.41 9.82 9.82 0.04 0.04 0.04	7.49 7.49 7.49 7.49 7.09	Standar	-20 (-29.5, 3 -19.4, -27.7, -24.1, -19.4, -27.7, -24.1, -19.4, -27.7, -24.1, -5.3, -5.8,	7 [-56.47 8 [-37.24] 1 [-52.92 8 [-46.19] 2 [-11.35 9 [-5.53 8 [-8.91 95% [-5.29; [-3.86, [-4.42; [-21.72; [-4.95; [-21.72; [-4.95; [-28.43; [-28.44; [-2.84; [-2.84; [-2.84; [-2.84]; [-2.84; [-2.84];[-2.84]; [-2.84];[-2.8	-Cl -2.66] -2.18] -2.18] -2.66] -2.18] 0.58] 0.54] 0.58] 0.54] 0.58] 0.54] 0.58] 0.54] 0.52] -0.42] -1.29] -0.42] 1.39] 0.84] 1.39]	0.8% 0.3% 0.6% 0.3% 0.4% 0.3% 0.4% 7.9% 6.7% 6.7% 10.0% 7.9% 6.4% 0.3% 7.7% 6.4% 0.3% 7.3% 6.4% 0.3% 15.4% 8.2% 0.3% 7.3% 15.4% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2	2.2% 0.8% 1.8% 0.9% 1.2% 11.4% 10.5% 100.0% Weight (random) 11.6% 8.0% 7.1% 5.5% 4.2% 0.8% 7.1% 0.3% 6.0% 7.1% 9.8% 7.7%	<0.00
	e.e 2008(8) .ee 2008(10) .ee 2008(10) .ee 2008(11) .ee 2008(12) .chun 2014(2) Common effects r Random effects r study TSAI 2008(1) Manu 2008(1) Manu 2008(1) Manu 2008(2) Manu 2012(1) Manu 2012(1) Manu 2014(2) Jang 2014(2) J	3 3 3 3 3 3 3 3 3 3 3 3 3 4 4 4 4 4 3	219.90 54.41 9.07 4.53 4.46 285.77 255.91 42 = 7.3325 9 = 7.5325 9 = 7.3325 9 = 7.5325 9 = 7.5325 9 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	$\begin{array}{c} 0 & 23.66 \\ 3.93 \\ 3.5.34 \\ 15.71 \\ 23.703 \\ 8 & 27.09 \\ 8 & 27.09 \\ 8 & 27.09 \\ 8 & 27.09 \\ 15.71 \\ 1.90 \\ 2.20 \\ 1.90 \\ 2.20 \\ 1.90 \\ 2.20 \\ 1.90 \\ 2.20 \\ 1.90 \\ 2.20 \\ 1.90 \\ 2.20 \\ 1.90 \\ 2.20 \\ 1.90 \\ 2.20 \\ 1.90 \\ 0.01 \\ 0.02 \\ 0.01 \\ 0.02 \\ 0.01 \\ 0.02 \\ 0.01 \\ 0.02 \\ 0.03 \\ 0.01 \\ 0.02 \\ 0.03 \\ 0.04 \\$	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	78; 78; 78; 78; 78; 78; 78; 78; 78; 78;	2.12 2: 2.12 2: 2.12 2: 2.12 2: 2.12 2: 2.12 2: 2.12 2: 3.73 2: 3.73 2: 3.73 2: 5.50 2.50 2.50 2.50 2.50 2.50 0.04 13.41 14.41	7.49 7.49 7.49 7.49 7.09	Standar	-20 (-29.5,	7 [-56.47 8 [-37.24] 1 [-52.92 8 [-46.19] 2 [-10.43 2 [-11.35 9 [-5.53 3 [-8.91 9 [-5.28; [-3.70; [-3.86; [-4.42; [-2.17.2; [-4.95; [-6.77; [-8.24; [-2.83; [-2.81,77] [-28.37] [-28.17] [-2.81,7] [-4.44] [-2.83,7] [-4.44] [-4.44] [-2.83,7] [-4.44] [-4.44] [-2.83,7] [-4.44] [-4.44] [-2.83,7] [-4.44] [-4.44] [-4.44] [-2.83,7] [-4.44] [-4.44] [-4.44] [-2.83,7] [-4.44] [-4.44] [-4.44] [-4.44] [-4.44] [-2.83,7] [-4.44] [-5.44] [-4.44]\\[-4.4	-Cl -2.60 ; -2.17; ; -0.23; ; -0.30, ; -2.66 ; -3.94 ; -0.30, ; -2.66 ; -3.94 ; -3.94 ; -0.30, ; -2.66 ; -3.94 ; -3.94 ; -3.94 ; -0.30, 0.54 ; -0.42] -0.42 ; -0.75 ; -1.27] , -0.23, 0.54 ; -0.23, 0.54 ; -0.24, 0.54 ; -0.24, 0.54 ; -0.24, 0.54 ; -0.24, 0.54 ; -0.25, 0.54 ; -0.24, 0.54 ; -0.24, 0.54 ; -0.24, 0.54 ; -0.25, 0.54 ; -0.25, 0.54 ; -0.25, 0.54 ; -0.26, 0.54 ; -0.27, 0.54 ; -0.27, 0.54 ; -0.27, 0.54 ; -0.27, 0.54 ; -0.27, 0.54 ; -0.27, 0.54 ; -0.27, 0.54 ; -0.27, 0.54 ; -0.29, 0.54 ; -0.29, 0.54 ; -0.29, 0.54 ; -0.29, 0.54 ; -0.29, 0.54 ; -0.29, 0.54 ; -0.29, 0.54 ; -0.29, 0.54 ; -0.29, 0.54 ; -0.29, 0.54 ; -0.29, 0.54 ; -0.29, 0.54 ; -0.29, 0.54 ; -0.29, 0.54 ; -0.29, 0.54 ; -0.29, -0.29, -0.29, -0.27, -0.27, -0.27, -0.27, -0.27, -0.29, -0	0.8% 0.3% 0.6% 0.3% 0.4% 0.4% 7.9% 6.7% 100.0% 	2.2% 0.8% 1.8% 0.9% 1.2% 11.4% 10.5% 100.0% **********************************	<0.00
	e.e 2008(8) .e.e 2008(10) .e.e 2008(10) .e.e 2008(11) .e.e 2008(12) .chun 2014(2) Common effect r Random effect r iteterogeneity: / ² = Study TSAI 2008 Manu 2008(1) Manu 2008(1) Manu 2008(1) Manu 2008(1) Manu 2008(2) Manu 2012(2) Manu 2012(2) Manu 2016(2) Chen 2016(2) Chen 2016(3) Wang 2017(2) MOON 2019(2) MOON	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	219.90 54.41 9.07 4.53 4.46 285.71 255.91 42 = 7.3325 92 92 92 92 92 92 92 92	$\begin{array}{c} 0 & 23.66 \\ 3.93 \\ 3.5.34 \\ 15.71 \\ 23.703 \\ 8 & 27.09 \\ 8 & 27.09 \\ 8 & 27.09 \\ 8 & 27.09 \\ 15.71 \\ 1.90 \\ 2.20 \\ 1.90 \\ 2.20 \\ 1.90 \\ 2.20 \\ 1.90 \\ 2.20 \\ 1.90 \\ 2.20 \\ 1.90 \\ 2.20 \\ 1.90 \\ 2.20 \\ 1.90 \\ 2.20 \\ 1.90 \\ 0.01 \\ 0.02 \\ 0.01 \\ 0.02 \\ 0.01 \\ 0.02 \\ 0.01 \\ 0.02 \\ 0.03 \\ 0.01 \\ 0.02 \\ 0.03 \\ 0.04 \\$	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	78; 78; 78; 78; 78; 78; 78; 78; 78; 78;	2.12 2: 2.12 2: 2.12 2: 2.12 2: 2.12 2: 2.12 2: 3.73 2: 3.73 2: 3.73 2: 3.73 2: 5.50 5.50 1.14.04 0.04 0.04 0.04 0.04 0.04 0.04	7.49 7.49 7.49 7.49 7.09	Standar	-20 (-29.5, 3 -19.4, -27.7, -24.1, -19.4, -27.7, -24.1, -5.3, -5.8, -5.	7 (-56.4) 8 (-37.24) 9 (-37.24) 9 (-10.43) 9 (-10.43) 9 (-10.43) 9 (-5.53) 9 (-5.29) (-3.80) (-3.80) (-3.80) (-3.80) (-3.80) (-4.82) (-21.72) (-21.72) (-21.72) (-21.72) (-2.83) (-3.80) (-4.84) (-2.83) (-2.84) (-2.8	(1.37) (1.37	0.8% 0.3% 0.6% 0.3% 0.3% 0.4% 7.9% 6.7% 100.0% 	2.2% 0.8% 1.8% 0.9% 1.2% 11.4% 10.5% 100.0% **********************************	<0.00 <0.00 P-val

FIGURE 7

Characteristic of *in vitro* studies regarding the effect of use of ursolic acid to treat chronic inflammatory and oxidative stress system lesions on inflammatory markers. Interleukin-1beta (IL-1 β) (A), Interleukin-6 (IL-6) (B), Interleukin-8 (IL-8) (C) and Tumor necrosis factor-alpha (TNF- α) (D).

individuals. Ursolic acid has been proposed as a therapeutic option for addressing conditions such as rheumatism, arthritis, and metabolic disorders (Kim et al., 2015; Nguyen

et al., 2021). Moreover, considering that older adults often contend with multiple medical conditions necessitating polypharmacy, ursolic acid's low potential for drug-drug

	SOD Study		perimer Mean	tal SD	Tot	Contro al Mean		Standardised Mean Difference	SMD	95%-CI	Weight (common)	Weight	P-val
				100/00/00				L	10.0000				
	TSAI 2008 Yu 2009(1)	10 3	7.62 5.07	0.23 0.07	10 3	5.62 5.17	0.15 0.91	1		[6.36; 13.37 [-1.73; 1.48		8.0% 9.0%	
	Yu 2009(2)	3	5.21	0.24	3	5.17	0.91	<u>∓</u>		[-1.55; 1.65		9.0%	
	Yu 2009(3)	3	5.17	0.27	3	5.17	0.91	÷	0.00	[-1.60; 1.60	12.8%	9.0%	
	Yu 2009(4)	3	5.79	0.07	3	5.17	0.91	÷	0.77	[-0.98; 2.51	10.7%	8.9%	
	Yu 2009(5)	3	6.06	0.27	3	5.17	0.91	<u>*</u>	1.06	[-0.81; 2.92	9.4%	8.9%	
	Samivel 2020(1) Samivel 2020(2)	6 6	15.76 6.82	0.85 0.21	6 6	15.72 15.72		📲		[-1.09; 1.18 [-20.66; -7.10		9.1% 5.8%	
	Samivel 2020(2)	6	11.36	0.68	6		0.81			[-20.00, -7.10		8.4%	
	Jia 2021(3)	3	44.25	4.50	3		6.75	-		[-0.28; 5.28		8.4%	
	Jia 2021(4)	3	56.25	6.75	3	26.25		· · ·		[-0.05; 7.14		7.9%	
	Wei 2022	3	253.19	19.15	3	159.57	17.02		4.12	[0.05; 8.19]	2.0%	7.6%	
	Common effect me	odel	52			52		5	0.40	[-0.17; 0.98] 100.0%		0.16
	Random effects m						г			[-2.14; 3.14		100.0%	0.71
	Heterogeneity: / ² = 8	5%, 7 =	19.5616	, p < 0.0	1		-20	0 -10 0 10	20				
В	MDA	F		4-1		Control							
	Study		perimer Mean	SD	Total	Control Mean	SD	Standardised Mea Difference	n SMD	95%-CI	Weight (common)	Weight (random)	P-val
	TSAI 2008	10	0.70	0.09	10	1.32	0.07		-7.36	[-10.04; -4.6	91 49 0%	49.0%	
	Yu 2009(1)	3	1.70	0.12	3	2.85	0.06			[-18.60; -0.7		4.4%	
	Yu 2009(2)	3	1.57	0.02	3	2.85	0.06	+-	-22.84	[-43.63; -2.0	4] 0.8%	0.8%	
	Yu 2009(3)	3	1.43	0.13	3	2.85	0.06		-11.19	[-21.48; -0.9	0] 3.3%	3.3%	
	Yu 2009(4)	3	1.24	0.06	3	2.85	0.06			[-40.91; -1.9		0.9%	
	Yu 2009(5) Jia 2021(3)	3	1.22 18.60	0.08 3.30	3	2.85 43.80	0.06 3.90			[-35.17; -1.6		1.2% 12.5%	
	Jia 2021(3)	3	14.70	3.30	3	43.80	3.90		-5.95	[-10.87; -0.2 [-11.59; -0.3	2] 11 1%	12.5%	
	Wei 2022	3	11.13	1.70	3	21.20	1.70		-4.73	[-9.31; -0.1	5] 16.8%	16.8%	
	Common effect me Random effects m		34		3	4		*		[-9.04; -5.2 [-9.04; -5.2		100.0%	<0.00
	Heterogeneity: $l^2 = 6^4$		0004	- 0.20						1 0.04, -0.2	1	100.0%	-0.00
-				- 0.00				-40 -20 0 2	0 40				
C	GSH	Ex	perimer	ntal		Control		Standardised Mean			Weight	Weight	
	Study	Total	Mean	SD	Total	Mean	SD	Difference	SMD	95%-CI	(common)		P-val
	TSAI 2008	10	53.00	3.00	10	45.00	3.00	1 🖶	2.55	[1.31; 3.79]	45.1%	45.1%	
	Samivel 2020(1)	6	23.30	2.23	6	18.28	1.49		2.44	[0.81; 4.08]		26.0%	
	Samivel 2020(2)	6	29.42		6	18.28	1.49		- 5.76	[2.76; 8.75]	7.7%	7.7%	
	Samivel 2020(3)	6	24.32	2.23	6	18.28	1.49		2.94	[1.13; 4.75]	21.1%	21.1%	
	Common effect me Random effects m		28		2	8		\$	2.85	[2.02; 3.69]			<0.00
									2.85	[2.02; 3.69]		100.0%	<0.00
			0.0001,	p = 0.25									
D	Heterogeneity: I ² = 2		0.0001,	p = 0.25				-5 0 5					
D	Heterogeneity: I ² = 2	7%, { < Ex	0.0001, cperime I Mean	ntal		Contro I Mean			ean SMD		Weight	Weight) P-va
D	Heterogeneity: I ² = 2 GPx Study	7%, 2 < Ex Tota	kperime I Mean	ntal SD	Tota	l Mean	SD	-5 0 5 Standardised Me	SMD	95%-CI	Weight (common	Weight) (random) P-val
D	Heterogeneity: $l^2 = 2$ GPx Study TSAI 2008	7%, 2 < Ex Tota	kperime I Mean 52.07	ntal SD 5.14	Tota 10	I Mean 46.93	SD	-5 0 5 Standardised Me	SMD 1.27	95%-CI [0.29; 2.2	Weight (common 5] 39.9%	Weight) (random 12.5%) P-val
D	Heterogeneity: I ² = 2 GPx Study	7%, 2 < Ex Tota	kperime I Mean	ntal SD 5.14 5.95	Tota	l Mean	SD 1.93 1.65	-5 0 5 Standardised Me	SMD 1.27 1.64	95%-CI [0.29; 2.2	Weight (common 5] 39.9% 2] 8.0%	Weight) (random) P-val
D	Heterogeneity: / ² = 2 GPx Study TSAI 2008 Yu 2009(1) Yu 2009(2) Yu 2009(3)	7%, <i>t</i> ² < Ex Tota 10 3 3 3 3	cperime 1 Mean 52.07 47.35 53.65 60.91	ntal SD 5.14 5.95 6.95 9.26	Tota 10 3 3 3	46.93 38.38 38.38 38.38	SD 1.93 1.65 1.65 1.65	-5 0 5 Standardised Me	SMD 1.27 1.64 2.41 2.70	95%-Cl [0.29; 2.2 [-0.55; 3.8 [-0.30; 5.1 [-0.23; 5.6	Weight (common 5] 39.9% 2] 8.0% 2] 5.2% 3] 4.5%	Weight) (random 12.5% 11.8% 11.4% 11.2%) P-va
D	Heterogeneity: /² = 2 GPx Study TSAI 2008 Yu 2009(1) Yu 2009(2) Yu 2009(3) Yu 2009(4)	7%, <i>t</i> < E Tota 10 3 3 3 3 3	52.07 47.35 53.65 60.91 63.20	5.14 5.95 6.95 9.26 9.92	Tota 10 3 3 3 3 3	46.93 38.38 38.38 38.38 38.38 38.38	SD 1.93 1.65 1.65 1.65 1.65	-5 0 5 Standardised Me	1.27 1.64 2.41 2.70 2.78	95%-Cl [0.29; 2.2 [-0.55; 3.8 [-0.30; 5.1 [-0.23; 5.6 [-0.21; 5.7	Weight (common 5] 39.9% 2] 8.0% 2] 5.2% 3] 4.5% 8] 4.3%	Weight) (random 12.5% 11.8% 11.4% 11.2% 11.1%) P-va
D	Heterogeneity: /² = 2 GPx Study TSAI 2008 Yu 2009(1) Yu 2009(2) Yu 2009(3) Yu 2009(4) Yu 2009(5)	7%, <i>t</i> < E) Tota 10 3 3 3 3 3 3 3 3	52.07 47.35 53.65 60.91 63.20 54.80	ntal SD 5.14 5.95 6.95 9.26 9.92 4.96	Tota 10 3 3 3 3 3 3 3	46.93 38.38 38.38 38.38 38.38 38.38 38.38	SD 1.93 1.65 1.65 1.65 1.65 1.65	-5 0 5 Standardised Me	1.27 1.64 2.41 2.70 2.78 3.54	95%-Cl [0.29; 2.2 [-0.55; 3.8 [-0.30; 5.1 [-0.23; 5.6 [-0.21; 5.7 [-0.05; 7.1	Weight (common 5] 39.9% 2] 8.0% 2] 5.2% 3] 4.5% 8] 4.3% 4] 3.0%	Weight) (random 12.5% 11.8% 11.4% 11.2% 11.1% 10.5%) P-val
D	Heterogeneity: /² = 2 GPx Study TSAI 2008 Yu 2009(1) Yu 2009(2) Yu 2009(3) Yu 2009(3) Yu 2009(5) Samiyel 2020(1)	7%, 2 < Ex Tota 10 3 3 3 3 3 6	52.07 47.35 53.65 60.91 63.20 54.80 14.66	ntal SD 5.14 5.95 6.95 9.26 9.92 4.96 0.64	Tota 10 3 3 3 3 3 3 3 6	46.93 38.38 38.38 38.38 38.38 38.38 38.38 38.38 14.92	SD 1.93 1.65 1.65 1.65 1.65 1.65 0.72	-5 0 5 Standardised Me	1.27 1.64 2.41 2.70 2.78 3.54 -0.35	95%-Cl [0.29; 2.2 [-0.55; 3.8 [-0.30; 5.1 [-0.23; 5.6 [-0.21; 5.7 [-0.05; 7.1 5 [-1.50; 0.7	Weight (common 5] 39.9% 2] 8.0% 2] 5.2% 3] 4.5% 8] 4.3% 8] 4.3% 9] 29.2%	Weight) (random 12.5% 11.8% 11.4% 11.2% 11.1% 10.5% 12.5%) P-val
D	Heterogeneity: /² = 2 GPx Study TSAI 2008 Yu 2009(1) Yu 2009(2) Yu 2009(3) Yu 2009(4) Yu 2009(5)	7%, <i>t</i> < E) Tota 10 3 3 3 3 3 3 3 3	52.07 47.35 53.65 60.91 63.20 54.80	ntal SD 5.14 5.95 6.95 9.26 9.92 4.96 0.64 0.25	Tota 10 3 3 3 3 3 3 3	46.93 38.38 38.38 38.38 38.38 38.38 38.38	SD 1.93 1.65 1.65 1.65 1.65 1.65 0.72 0.72	-5 0 5 Standardised Me	SMD 1.27 1.64 2.41 2.70 2.78 3.54 -0.35 -12.8	95%-Cl [0.29; 2.2 [-0.55; 3.8 [-0.30; 5.1 [-0.23; 5.6 [-0.21; 5.7 [-0.05; 7.1	Weight (common) 5] 39.9% 2] 8.0% 2] 5.2% 3] 4.5% 8] 4.3% 4] 3.0% 9] 29.2% 55] 1.0%	Weight) (random 12.5% 11.8% 11.4% 11.2% 11.1% 10.5%) P-val
D	Heterogeneity: /² = 2 GPx Study TSAI 2008 Yu 2009(1) Yu 2009(2) Yu 2009(2) Yu 2009(3) Yu 2009(4) Yu 2009(4) Yu 2009(5) Samivel 2020(2) Samivel 2020(2) Samivel 2020(2) Samivel 2020(2)	7%, 2 < E Tota 10 3 3 3 3 6 6 6 6 10 10 10 10 10 10 10 10 10 10	cperime 52.07 47.35 53.65 60.91 63.20 54.80 14.66 7.42	ntal SD 5.14 5.95 6.95 9.26 9.92 4.96 0.64 0.25	Tota 10 3 3 3 3 3 3 6 6 6	46.93 38.38 38.38 38.38 38.38 38.38 38.38 38.38 14.92 14.92	SD 1.93 1.65 1.65 1.65 1.65 1.65 0.72 0.72	-5 0 5 Standardised Me	SMD 1.27 1.64 2.41 2.70 2.78 3.54 -0.35 -12.8 -5.28 0.62	95%-Cl [0.29; 2.2 [-0.55; 3.8 [-0.30; 5.1 [-0.23; 5.6 [-0.21; 5.7 [-0.05; 7.1 5 [-1.50; 0.7 4 [-19.13; -6.9 3 [-8.07; -2.5 [0.00; 1.2	Weight (common 5] 39.9% 2] 5.2% 3] 4.5% 8] 4.3% 4] 3.0% 9] 29.2% 55] 1.0% 60] 4.9%	Weight) (random 12.5% 11.4% 11.2% 11.1% 10.5% 12.5% 7.8% 11.3%	0.04
D	Heterogeneity: /² = 2 GPx Study TSAI 2008 Yu 2009(1) Yu 2009(2) Yu 2009(3) Yu 2009(3) Yu 2009(4) Yu 2009(5) Samivel 2020(1) Samivel 2020(2) Samivel 2020(2) Samivel 2020(2) Common effect m Random effects m	7%, 2 < E 2 Tota 10 3 3 3 3 6 6 6 6 6 10 0 0 0 0 0 0 0 0 0 0 0 0 0	cperime 52.07 47.35 53.65 60.91 63.20 54.80 14.66 7.42 11.02 43	5.14 5.95 6.95 9.26 9.92 4.96 0.64 0.25 0.64	Tota 10 3 3 3 3 6 6 6	 Mean 46.93 38.38 38.38 38.38 38.38 38.38 38.38 14.92 14.92 14.92 	SD 1.93 1.65 1.65 1.65 1.65 1.65 0.72 0.72	-5 0 5 Standardised Me Difference	SMD 1.27 1.64 2.41 2.70 2.78 3.54 -0.35 -12.8 -5.28 0.62 -0.03	95%-Cl [0.29; 2.2 [-0.55; 3.8 [-0.30; 5.1 [-0.23; 5.6 [-0.21; 5.7, [-0.05; 7.1 5 [-1.50; 0.7 4 [-19.13; -6.4] 3 [-8.07; -2.5]	Weight (common 5] 39.9% 2] 5.2% 3] 4.5% 8] 4.3% 4] 3.0% 9] 29.2% 55] 1.0% 60] 4.9%	Weight) (random 12.5% 11.8% 11.4% 11.2% 11.1% 10.5% 12.5% 7.8% 11.3%	0.04
	Heterogeneity: /² = 2 Study TSAI 2008 Yu 2009(1) Yu 2009(2) Yu 2009(2) Yu 2009(3) Yu 2009(4) Yu 2009(5) Samivel 2020(2) Samivel 2020	7%, 2 < E 2 Tota 10 3 3 3 3 6 6 6 6 6 10 0 0 0 0 0 0 0 0 0 0 0 0 0	cperime 52.07 47.35 53.65 60.91 63.20 54.80 14.66 7.42 11.02 43	5.14 5.95 6.95 9.26 9.92 4.96 0.64 0.25 0.64	Tota 10 3 3 3 3 6 6 6	 Mean 46.93 38.38 38.38 38.38 38.38 38.38 38.38 14.92 14.92 14.92 	SD 1.93 1.65 1.65 1.65 1.65 1.65 0.72 0.72	-5 0 5 Standardised Me	SMD 1.27 1.64 2.41 2.70 2.78 3.54 -0.35 -12.8 -5.28 0.62 -0.03	95%-Cl [0.29; 2.2 [-0.55; 3.8 [-0.30; 5.1 [-0.23; 5.6 [-0.21; 5.7 [-0.05; 7.1 5 [-1.50; 0.7 4 [-19.13; -6.9 3 [-8.07; -2.5 [0.00; 1.2	Weight (common 5] 39.9% 2] 5.2% 3] 4.5% 8] 4.3% 4] 3.0% 9] 29.2% 55] 1.0% 60] 4.9%	Weight) (random 12.5% 11.4% 11.2% 11.1% 10.5% 12.5% 7.8% 11.3%) P-val 0.04 0.98
	Heterogeneity: /² = 2 GPx Study TSAI 2008 Yu 2009(1) Yu 2009(2) Yu 2009(2) Yu 2009(2) Yu 2009(4) Yu 2009(5) Samivel 2020(2) Samivel 2020(2) Common effect m Heterogeneity: /² = 8 CAT	7%, 7 < Ex Tota 10 3 3 3 3 6 6 6 6 10 33 3 3 3 3 3 3 3 3 3 3 3 3	52.07 47.35 53.65 60.91 63.20 54.80 14.66 7.42 11.02 43 = 16.082	ntal SD 5.14 5.95 6.95 9.26 9.92 4.96 0.64 0.25 0.64	Tota 10 3 3 3 6 6 6 6	I Mean 46.93 38.38 38.38 38.38 38.38 38.38 14.92 14.92 14.92 14.92 14.92	SD 1.93 1.65 1.65 1.65 1.65 0.72 0.72 0.72	Standardised Mean	SMD 1.27 1.64 2.41 2.70 2.78 3.54 -0.35 -12.8 -5.28 0.62 -0.03 10 15	95%-Cl [0.29; 22 [-0.55; 33 [-0.30; 5.1 [-0.21; 5.7 [-0.05; 7.1 [-0.21; 5.7 [-0.05; 7.1 [-1.50; 0.7 4 [-19.13; -6.4 [-8.07; -2.5 [0.00; 1.2 [-2.83; 2.7	Weight (common 5] 39.9% 2] 8.0% 2] 5.2% 3] 4.5% 4] 3.0% 55] 1.0% 0] 4.9% 4] 100.0% 8]	Weight) (random 12.5% 11.4% 11.4% 11.2% 11.3% 12.5% 7.8% 11.3% 100.0% Weight	0.04 0.98
	Heterogeneity: /² = 2 Study TSAI 2008 Yu 2009(1) Yu 2009(2) Yu 2009(2) Yu 2009(3) Yu 2009(4) Yu 2009(5) Samivel 2020(2) Samivel 2020	7%, 7 < Ex Tota 10 3 3 3 3 6 6 6 6 10 33 3 3 3 3 3 3 3 3 3 3 3 3	cperime 1 Mean 52.07 47.35 53.65 60.91 63.20 54.80 14.66 7.42 11.02 43 = 16.082	ntal SD 5.14 5.95 6.95 9.26 9.92 4.96 0.64 0.25 0.64	Tota 10 3 3 3 6 6 6 6	 Mean 46.93 38.38 38.38 38.38 38.38 38.38 14.92 14.92 14.92 14.92 14.92 	SD 1.93 1.65 1.65 1.65 1.65 1.65 0.72 0.72	-5 0 5 Standardised Mu Difference	SMD 1.27 1.64 2.41 2.70 2.78 3.54 -0.35 -12.8 -5.28 0.62 -0.03	95%-Cl [0.29; 2.2 [-0.55; 3.8 [-0.30; 5.1 [-0.23; 5.6 [-0.21; 5.7 [-0.05; 7.1 5 [-1.50; 0.7 4 [-19.13; -6.9 3 [-8.07; -2.5 [0.00; 1.2	Weight (common 5] 39.9% 2] 8.0% 2] 5.2% 3] 4.5% 8] 4.3% 4] 3.0% 9] 29.2% 55] 1.0% 55] 1.0% 8]	Weight) (random 12.5% 11.4% 11.4% 11.2% 11.3% 12.5% 7.8% 11.3% 100.0% Weight	0.04 0.98
	Heterogeneity: /² = 2 GPx Study TSAI 2008 Yu 2009(1) Yu 2009(2) Yu 2009(2) Yu 2009(2) Yu 2009(3) Yu 2009(5) Samivel 2020(1) Samivel 2020(2) Samivel 2020(3) Common effect m Heterogeneity: /² = 8 CAT Study TSAI 2008	$7\%, t^2 < 25$ Tota 10 3 3 3 3 3 3 3 6 6 6 6 6 10 10 3 3 3 3 3 3 3 3 3 3 3 3 3	kperime 1 Mean 52.07 47.35 53.65 60.91 63.20 54.80 7.42 11.02 43 = 16.082° kperime k Mean 2.22 2.22	sp 5.14 5.95 9.26 9.92 4.96 0.64 0.25 0.64 ntal SD 0.07	Tota 10 3 3 3 3 3 6 6 6 6 1 1 1 1 Total	I Mean 46.93 38.38 38.38 38.38 38.38 38.38 38.38 14.92 14.92 14.92 13 Control Mean 1.22	SD 1.93 1.65 1.65 1.65 1.65 0.72 0.72 0.72 0.72 SD 0.05	Standardised Mean	SMD 1.27 1.64 2.41 2.70 2.78 3.54 -0.35 -12.8 -5.28 0.62 -0.03 10 15 SMD 15.74	95%-Cl [0.29; 2.2 [-0.55; 3.8] -0.30; 5.6 [-0.21; 5.7 [-0.65; 7.1 [-0.21; 5.7 [-0.65; 7.1 [-1.50; 0.7 [-1.50; 0.7 [-1.50; 0.7 [-1.50; 0.7 [-1.50; 0.7] -2.83; 2.7 95%-Cl [10.26; 21.2	Weight (common [] 30,9% [2] 8.0% [2] 5.2% [3] 4.5% [3] 4.5% [3] 9.9% [3] 4.5% [3] 4.3% [6] 9.92,2% [3] 0.0%	Weight) (random 12.5% 11.8% 11.4% 11.2% 11.1% 7.8% 11.3% 100.0% Weight) (random)	0.04 0.98
	Heterogeneity: /² = 2 GPx Study TSAI 2008 Yu 2009(1) Yu 2009(2) Yu 2009(2) Yu 2009(3) Yu 2009(5) Samivel 2020(2) Samivel 2020(2) Sa	7%, $\hat{\tau} < \frac{1}{5}$ Tota 10 3 3 3 3 6 6 6 6 6 10 3 3 3 3 3 3 3 3 3 3 3 3 3	xperime 52.07 53.65 53.65 54.80 14.66 7.42 11.02 43 = 16.082 ² xperime Mean 2.22 2.4.71	ntal SD 5.14 5.95 6.95 9.92 0.64 0.25 0.64 ntal SD 0.07 1.67	Tota 10 3 3 3 3 3 6 6 6 6 6 7 11 11 10 3	I Mean 46.93 38.38 38.38 38.38 38.38 38.38 38.38 14.92 14.92 14.92 14.92 14.92 14.92 14.92 14.92 14.92 12.22 23.53	SD 1.93 1.65 1.65 1.65 1.65 0.72 0.72 0.72 0.72 0.72 0.72 0.72 0.72 0.72	Standardised Mean	SMD 1.27 1.64 2.41 2.70 2.78 3.54 -0.35 -12.8 -5.26 0.62 -0.03 10 15 SMD 15.74 0.66	95%-Cl [0.29; 2.2 [-0.30; 5.3.8 [-0.30; 5.5; 3.8 [-0.21; 6.7; [-0.05; 7.1 [-0.05; 7.1 [-1.90; 7.1 [-1.90; 7.2; 5 [0.00; 1.2 [-2.83; 2.7 95%-Cl [10.26; 21.2 [-1.05; 2.3	Weight (common 5] 39.9% 2] 8.0% 2] 5.2% 3] 4.5% 3] 4.5% 3] 4.5% 6] 4.3% 4] 3.0% 9] 29.2% 55] 1.0% 60] 4.9% 4] 100.0% 8] Weight (common) 12] 3.1% 7] 31.8%	Weight) (random 12.5% 11.4% 11.2% 11.1% 12.5% 7.8% 11.3% 11.3% 100.0%	0.04 0.98
	Heterogeneity: /² = 2 GPx Study TSAI 2008 Yu 2009(1) Yu 2009(2) Yu 2009(2) Yu 2009(3) Yu 2009(4) Yu 2009(4) Yu 2009(4) Yu 2009(4) Samivel 2020(2) Samivel 2020(2) Common effect m Heterogeneity: /² = 8 CAT Study TSAI 2008 Yu 2009(1) Yu 2009(2)	$7\%, \hat{t} < $ Ex. Tota 100 3 3 3 3 3 6 6 6 6 6 0 0 0 0 4 1 0 3 3 3 3 6 5 6 7 5 7 7 7 7 0 7 8 7 7 7 7 7 7 7 7 7 7 7 7 7	cperime 52.07 47.35 53.65 60.91 14.66 63.20 54.80 11.02 43 cperime Mean 2.22 24.71 2.7.49	ntal SD 5.14 5.95 6.95 9.926 0.64 9.92 4.96 0.25 0.25 0.64 ntal SD 0.07 1.67 1.48	Tota 10 3 3 3 3 6 6 6 6 6 6 7 11 11	I Mean 46.93 38.38 38.38 38.38 38.38 14.92 14.92 14.92 14.92 14.92 12 23.53	SD 1.93 1.65 1.65 1.65 0.72 0.72 0.72 0.72 0.72 0.72 0.72 0.72 0.72 0.72 0.72	Standardised Mean	SMD 1.27 1.64 2.41 2.70 2.78 3.54 -0.28 -12.8 -5.28 0.62 -0.03 10 15 SMD 15.74 0.64 2.42	95%-Cl [0.29; 2.2 [-0.55; 3.8 [-0.30; 5.1 [-0.21; 5.7; [-0.05; 7.1; [-0.05; 7.1; [-0.05; 7.1; [-1.50; 0.7; -2.5; [0.00; 1.2; [-2.83; 2.7; 95%-Cl [10.26; 21.2; [-0.30; 5.1; [-	Weight (common 5] 39,9% 2] 8.0% 2] 5.2% 3] 4.5% 8] 4.3% 9] 29,2% 55] 1.0% 00] 4.9% 4] 100.0% 8] Weight (common) 12] 3.1% 3] 12.6%	Weight) (random 12.5% 11.8% 11.4% 11.1% 10.5% 12.5% 7.8% 11.3% 100.0% Weight) (random) 11.3% 12.2%	0.04
	Heterogeneity: /² = 2 GPx Study TSAI 2008 Yu 2009(1) Yu 2009(2) Yu 2009(2) Yu 2009(3) Yu 2009(5) Samivel 2020(2) Samivel 2020(2) Sa	$7\%, t^2 < \frac{1}{10}$	Appendix Appendix	ntal SD 5.14 5.95 6.95 9.26 0.64 0.25 0.64 ntal SD 0.07 1.67 1.48	Total 10 3 3 3 3 6 6 6 6 6 6 7 11 10 3 3 3 3 3	I Mean 46.93 38.38 38.38 38.38 38.38 38.38 14.92 14.92 14.92 14.92 13 Image: Control Mean 1.22 23.53 23.53 23.53	SD 1.93 1.65 1.65 1.65 1.65 0.72 0.72 0.72 0.72 0.72 0.72	Standardised Mean	SMD 1.27 1.64 2.41 2.70 2.78 3.54 -0.35 -12.8 -5.28 0.62 -0.03 10 15 SMD 15.74 0.66 2.42 8.42	95%-Cl [0.29; 2.2 [-0.30; 5.1; [-0.30; 5.1; [-0.21; 5.7; [-0.05; 7.1; [-0.35; 7.1; [-0.35; 7.1; [-0.35; 7.1; [-1.50; 0.7; 4[-19:13; -6]; [-1.60; 7.2; [0.00; 1.2; [-1.65; 2.3; [-1.55; 2.3; [-0.30; 5.1; [-0.61; 162; 2.3;] -0.61; 162; 2.3; [-0.61; 162; 2.3; [-0.61; 162; 2.3;] -0.61; 162; 2.3; [-0.61; 162; 2.3;] -0.61; 162; 2.3; [-0.61; 162;	Weight (common 5] 39.9% 2] 8.0% 2] 5.2% 3] 4.5% 3] 4.5% 9] 29.2% 5] 1.0% 9] 4.3% 4] 100.0% 8] Weight (common) 2] 3.1% 7] 31.8% 3] 12.6% 2] 1.5%	Weight) (random 12.5% 11.4% 11.2% 11.1% 10.5% 12.5% 11.3% 100.0% Weight) (random) 11.3% 12.4% 12.4% 12.4% 12.4% 12.4% 12.5%	0.04 0.98
	Heterogeneity: /² = 2 GPx Study TSAI 2008 Yu 2009(1) Yu 2009(2) Yu 2009(2) Yu 2009(3) Yu 2009(4) Yu 2009(4) Yu 2009(4) Yu 2009(4) Samivel 2020(2) Samivel 2020(2) Common effect m Heterogeneity: /² = 8 CAT Study TSAI 2008 Yu 2009(1) Yu 2009(2)	$7\%, \hat{t} < $ Ex. Tota 100 3 3 3 3 3 6 6 6 6 6 0 0 0 0 4 1 0 3 3 3 3 6 5 6 7 5 7 7 7 7 0 7 8 7 7 7 7 7 7 7 7 7 7 7 7 7	cperime 52.07 47.35 53.65 60.91 14.66 63.20 54.80 11.02 43 cperime Mean 2.22 24.71 2.7.49	ntal SD 5.14 5.95 6.95 9.926 0.64 9.92 4.96 0.25 0.64 0.25 0.64 SD 0.25 0.64 1.48	Tota 10 3 3 3 3 6 6 6 6 6 6 7 11 11	I Mean 46.93 38.38 38.38 38.38 38.38 14.92 14.92 14.92 14.92 14.92 12 23.53	SD 1.93 1.65 1.65 1.65 0.72 0.72 0.72 0.72 0.72 0.72 0.72 0.72 0.72 0.72 0.72	Standardised Mean	SMD 1.27 1.64 2.41 2.70 2.78 3.54 -0.28 -12.8 -5.28 0.62 -0.03 10 15 SMD 15.74 0.64 2.42	95%-Cl [0.29; 2.2 [-0.55; 3.8 [-0.30; 5.1 [-0.21; 5.7 [-0.55; 7.1 [-1.50; 7.7 [-1.50; 7.7] -2.5 [-2.5] [-2.5] [-1.50; 7.7 [-1.50; 7.7 [-1.50; 7.7] -1.50; 7	Weight (common 5] 39,9% 2] 8.0% 2] 5.2% 3] 4.5% 8] 4.3% 4] 3.0% 9] 29.2% 55] 1.0% 00] 4.9% 4] 100.0% 8] Weight (common) 22] 3.1% 3] 12.6% 2] 1.5% 7] 0.7%	Weight) (random 12.5% 11.8% 11.4% 11.1% 10.5% 12.5% 7.8% 11.3% 100.0% Weight) (random) 11.3% 12.2%	0.04 0.98
	Heterogeneity: /² = 2 GPx Study TSAI 2008 Yu 2009(1) Yu 2009(2) Yu 2009(2) Yu 2009(3) Yu 2009(4) Yu 2009(5) Samivel 2020(2) Samivel 2020(2) Samivel 2020(2) Samivel 2020(2) Samivel 2020(2) Samivel 2020(2) Samivel 2020(2) Samivel 2020(2) Samivel 2020(2) Samivel 2020(2) Yu 2009(2) Yu 2009(3) Yu 2009(4) Yu 2009(5) Samivel 2020(1)	7%, <i>f</i> < Ex Tota 10 3 3 3 3 3 6 6 6 6 6 6 6 6 6 6 6 6 7 8 7 7 8 7 7 7 8 7 7 7 8 7 7 7 8 7 7 7 7 7 7 7 7 7 7 7 7 7	coperime I Mean 52.07 47.35 53.65 60.91 63.20 54.80 14.66 7.42 11.02 43 cperime Mean 2.22 24.71 2.42.71 34.33 38.60 39.47 12.12 12.12	ntal SD 5.14 5.95 9.92 9.92 9.92 0.64 0.25 0.64 7, p < 0.0 ntal SD 0.07 1.48 0.93 0.74 1.48 0.93 0.74 1.48	Tota 10 3 3 3 6 6 6 6 6 6 1 1 1 1 10 3 3 3 3 3 3	46.93 38.38 38.35 32.35,35	SD 1.93 1.65 1.65 1.65 1.65 0.72 0.72 0.72 0.72 0.72 0.72 0.72	Standardised Mean	SMD 1.27 1.64 2.41 2.70 2.78 3.54 -0.35 -12.8 -5.28 0.62 -0.03 10 15 SMD 15.74 0.66 2.42 8.42 -12.66 9.72 -2.26	95%-Cl [0.29; 2.2 [-0.35; 3.8 [-0.30; 5.1 [-0.21; 6.7; [-0.5; 7.1 [-1.50; 0.7 [-1.50; 0.7 4 [-19.3], -6], 3 [-8.07; -2.5 [0.00; 1.2 95%-Cl [10.26; 21.2 [-1.05; 24.2 [-1.05; 24.2 [0.7; 18.6 [-3.8], -0], [-3.8], -0]	Weight (common 5] 39.9% 2] 8.0% 2] 5.2% 3] 4.5% 3] 4.5% 3] 4.5% 6] 4.3% 4] 3.0% 9] 29.2% 55] 1.0% 60] 4.9% 4] 100.0% 8] Weight (common) (2] 3.1% 7] 3.1.8% 7] 0.7% 9] 1.2% 9] 37.8%	Weight) (random 12.5% 11.4% 11.2% 11.1% 12.5% 7.8% 11.3% 11.3% 100.0% Weight) (random) 11.3% 12.4% 12.2% 10.3% 12.4%	0.04 0.98
	Heterogeneity: /² = 2 GPx Study TSAI 2008 Yu 2009(1) Yu 2009(2) Yu 2009(2) Yu 2009(3) Yu 2009(5) Samivel 2020(1) Samivel 2020(2) Samivel 2020(3) Common effect m Heterogeneity: /² = 8 CAT Study TSAI 2008 Yu 2009(1) Yu 2009(2) Yu 2009(2) Yu 2009(2) Yu 2009(3) Yu 2009(4) Yu 2009(4) Yu 2009(5) Samivel 2020(1) Samivel 2020(1) Samivel 2020(2)	7%, f < Ex Tota 10 3 3 3 3 6 6 6 6 6 6 6 6 6 6 7 5 7 7 7 7 7 7 7 7	cperime Mean 52.07 47.35 53.65 60.91 63.20 54.80 60.41 43 = 16.082? cperime Mean 2.22 24.71 27.49 34.33 38.50 39.47 5.93	ntal SD 5.14 5.95 6.95 9.92 4.96 0.64 0.25 0.64 r, p < 0.0	Tota 10 3 3 3 3 3 6 6 6 10 3 3 3 3 3 6 6 6	46.93 38.38 38.35 32.35,3 23.55 32.35,3 33.55 35.55 35	SD 1.93 1.65 1.65 1.65 1.65 0.72 0.72 0.72 0.72 0.72 0.72 0.72 0.72 0.72	Standardised Mean	SMD 1.27 1.64 2.41 2.70 2.78 3.54 -0.35 -12.88 -5.26 0.62 -0.03 10 15 SMD 15.74 0.66 2.42 -12.84 8.42 -12.84 9.72 -2.26 -12.44 -2.26 -12.44 -2.41 -2.78 -2.28	95%-Cl [0.29; 2.2 [-0.35; 3.8 [-0.30; 5.1] -0.21; 5.7 [-0.05; 7.1 [-0.21; 5.7 [-0.05; 7.1 [-1.50; 0.7 4[-19:3]; -6.4 [-1.80; 7.2; [0.00; 1.2 [-1.80; 7.2; [0.00; 1.2 [-2.83; 2.7 95%-Cl [10.26; 21.2 [-1.05; 2.3 [0.75; 1.8 [-1.85; -0.3 [-1.85; -0.3] -1.85; -0.3 [-1.85; -0.3] -1.85; -0.35; -0.35; -0.35; -0.35; -0.35; -0.35; -0.35; -0.35;	Weight (common 5] 39.9% 2] 8.0% 2] 5.2% 3] 4.5% 3] 4.5% 9] 29.2% 5] 1.0% 60] 4.9% 4] 100.0% 8] Weight (common) 2] 3.1% 7] 1.5% 7] 0.7% 9] 1.2% 9] 3.7.8% 5] 2.5.%	Weight) (random 12.5% 11.8% 11.8% 11.2% 11.1% 7.8% 11.3% 100.0% Weight) (random) 11.3% 12.4% 12.4% 12.4% 12.4% 12.4% 12.4% 12.4% 12.4% 11.2% 11.3%	0.04 0.98
	Heterogeneity: /² = 2 GPx Study TSAI 2008 Yu 2009(1) Yu 2009(2) Yu 2009(2) Yu 2009(3) Yu 2009(4) Yu 2009(5) Samivel 2020(2) Samivel 2020(2) Samivel 2020(2) Samivel 2020(2) Samivel 2020(2) Samivel 2020(2) Samivel 2020(2) Samivel 2020(2) Samivel 2020(2) Samivel 2020(2) Yu 2009(2) Yu 2009(3) Yu 2009(4) Yu 2009(5) Samivel 2020(1)	7%, <i>f</i> < Ex Tota 10 3 3 3 3 3 6 6 6 6 6 6 6 6 6 6 6 6 7 8 7 7 8 7 7 7 8 7 7 7 8 7 7 7 8 7 7 7 7 7 7 7 7 7 7 7 7 7	coperime I Mean 52.07 47.35 53.65 60.91 63.20 54.80 14.66 7.42 11.02 43 cperime Mean 2.22 24.71 2.42.71 34.33 38.60 39.47 12.12 12.12	ntal SD 5.14 5.95 9.92 9.92 9.92 0.64 0.25 0.64 7, p < 0.0 ntal SD 0.07 1.48 0.93 0.74 1.48 0.93 0.74 1.48	Tota 10 3 3 3 3 6 6 6 6 7 11 10 3 3 3 3 6 6	46.93 38.38 38.35 32.35,35	SD 1.93 1.65 1.65 1.65 1.65 0.72 0.72 0.72 0.72 0.72 0.72 0.72	Standardised Mean	SMD 1.27 1.64 2.41 2.70 2.78 3.54 -0.35 -12.88 -5.26 0.62 -0.03 10 15 SMD 15.74 0.66 2.42 -12.84 8.42 -12.84 9.72 -2.26 -12.44 -2.26 -12.44 -2.41 -2.78 -2.28	95%-Cl [0.29; 2.2 [-0.35; 3.8 [-0.30; 5.1 [-0.21; 6.7; [-0.5; 7.1 [-1.50; 0.7 [-1.50; 0.7 4 [-19.3], -6], 3 [-8.07; -2.5 [0.00; 1.2 95%-Cl [10.26; 21.2 [-1.05; 24.2 [-1.05; 24.2 [0.7; 18.6 [-3.8], -0], [-3.8], -0]	Weight (common 5] 39.9% 2] 8.0% 2] 5.2% 3] 4.5% 3] 4.5% 9] 29.2% 5] 1.0% 60] 4.9% 4] 100.0% 8] Weight (common) 2] 3.1% 7] 1.5% 7] 0.7% 9] 1.2% 9] 3.7.8% 5] 2.5.%	Weight) (random 12.5% 11.4% 11.2% 11.1% 12.5% 7.8% 11.3% 11.3% 100.0% Weight) (random) 11.3% 12.4% 12.2% 10.3% 12.4%	0.04 0.98
	Heterogeneity: /² = 2 GPx Study TSAI 2008 Yu 2009(1) Yu 2009(2) Yu 2009(2) Yu 2009(3) Yu 2009(5) Samivel 2020(1) Samivel 2020(2) Samivel 2020(3) Common effect m Heterogeneity: /² = 8 CAT Study TSAI 2008 Yu 2009(1) Yu 2009(2) Yu 2009(2) Yu 2009(2) Yu 2009(3) Yu 2009(4) Yu 2009(4) Yu 2009(5) Samivel 2020(1) Samivel 2020(1) Samivel 2020(2)	7%, $\hat{t} < Ex Tota 10 3 3 3 3 6 6 6 6 6 10 3 3 3 3 3 3 3 3 3 3 3 3 3$	cperime Mean 52.07 47.35 53.65 60.91 63.20 54.80 60.41 43 = 16.082? cperime Mean 2.22 24.71 27.49 34.33 38.50 39.47 5.93	ntal SD 5.14 5.95 6.95 9.92 4.96 0.64 0.25 0.64 r, p < 0.0	Tota 10 3 3 3 3 3 6 6 6 6 7 10 3 3 3 3 6 6 6 6 6	46.93 38.38 38.35 32.35,3 23.55 32.35,3 33.55 35.55 35	SD 1.93 1.65 1.65 1.65 1.65 0.72 0.72 0.72 0.72 0.72 0.72 0.72 0.72 0.72	Standardised Mean	SMD 1.27 1.64 2.41 2.70 3.54 -0.33 SMD 10 15 74 -0.33 SMD	95%-Cl [0.29; 2.2 [-0.35; 3.8 [-0.30; 5.1] -0.21; 5.7 [-0.05; 7.1 [-0.21; 5.7 [-0.05; 7.1 [-1.50; 0.7 4[-19:3]; -6.4 [-1.80; 7.2; [0.00; 1.2 [-1.80; 7.2; [0.00; 1.2 [-2.83; 2.7 95%-Cl [10.26; 21.2 [-1.05; 2.3 [0.75; 1.8 [-1.85; -0.3 [-1.85; -0.3] -1.85; -0.3 [-1.85; -0.3] -1.85; -0.35; -0.35; -0.35; -0.35; -0.35; -0.35; -0.35; -0.35;	Weight (common 5] 39.9% 2] 8.0% 2] 5.2% 3] 4.5% 3] 4.5% 3] 4.5% 5] 1.0% 0] 29.2% 6] 4.3% 4] 100.0% 8] Weight (common) 12] 3.1% 7] 0.7% 9] 1.2% 1 1.5% 9] 1.2% 9] 1.2% 9] 1.2% 9] 1.2% 9] 1.2% 9] 3.1% 8] 8.8%	Weight) (random 12.5% 11.8% 11.4% 11.1% 12.5% 7.8% 11.3% 	0.04 0.98

FIGURE 8

Characteristic of *in vitro* studies regarding the effect of use of ursolic acid to treat chronic inflammatory and oxidative stress system lesions on antioxidant markers. Superoxide dismutase (SOD) (A), Malondialdehyde (MDA) (B), Glutathione (GSH) (C), Glutathione peroxidase (GPx) (D) and Catalase (CAT) (E).

interactions renders it even more advantageous. Consequently, older adults grappling with chronic inflammatory and oxidative stress-related issues stand to benefit significantly from the potential therapeutic effects of ursolic acid.

While we aimed for a comprehensive review in this study, it is essential to acknowledge its limitations: 1) We did not assess clinical outcomes and there are no ongoing randomized controlled trials assessing the effect of ursolic acid on clinical

outcomes. 2) Despite our efforts to mitigate heterogeneity through regression and subgroup analyses, substantial heterogeneity persisted in certain parameters due to the limited number of included studies. Exclusion of individual studies did not significantly alter this heterogeneity. 3) In the majority of experimental studies, there was a lack of information regarding blinding procedures for participants, personnel, and outcome assessment. This omission introduces uncertainty regarding the risk of bias, particularly in terms of performance and detection bias. The strength of this study lies in its comprehensive systematic review of all relevant animal and in vitro studies. Ursolic acid, while promising, remains an unproven natural compound. Nonetheless, our findings underscore the potential role of ursolic acid in antiinflammatory processes and in enhancing antioxidant defense mechanisms.

5 Conclusion

This meta-analysis suggests that ursolic acid may indeed lower levels of inflammatory cytokines, increase antioxidant enzyme levels, and reduce oxidative stress levels. Notably, it appears that cells and animals with existing inflammatory responses may benefit more from ursolic acid compared to healthy states. This study addresses the controversy over the effects of ursolic acid on inflammatory and oxidative stress processes and provides a basis for future applications of ursolic acid. To advance this field of research, it is crucial to conduct future studies with heightened methodological precision, larger sample sizes, and increased consistency in parameters such as dosage/concentration and route of administration. By doing so, we can gain a clearer understanding of the strength of the relationship between ursolic acid and inflammation and oxidative stress. This can ultimately pave the way for more definitive large-scale randomized controlled trials, both for treatment and prevention purposes, which are clearly warranted.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

References

Balduzzi, S., Rücker, G., and Schwarzer, G. (2019). How to perform a meta-analysis with R: A practical tutorial. *Evid. Based Ment. Health* 22 (4), 153–160. doi:10.1136/ebmental-2019-300117

Bent, R., Moll, L., Grabbe, S., and Bros, M. (2018). Interleukin-1 beta-A friend or foe in malignancies? Int. J. Mol. Sci. 19 (8), 2155. doi:10.3390/ijms19082155

Bernhard, S., Hug, S., Stratmann, A. E. P., Erber, M., Vidoni, L., Knapp, C. L., et al. (2021). Interleukin 8 elicits rapid physiological changes in neutrophils that are altered by inflammatory conditions. *J. Innate Immun.* 13 (4), 225–241. doi:10.1159/000514885

Burgos-Morón, E., Abad-Jiménez, Z., Marañón, A. M., Iannantuoni, F., Escribano-López, I., López-Domènech, S., et al. (2019). Relationship between oxidative stress, ER stress, and inflammation in type 2 diabetes: The battle continues. *J. Clin. Med.* 8 (9), 1385. doi:10.3390/jcm8091385

Dinarello, C. A. (2005). Blocking IL-1 in systemic inflammation. J. Exp. Med. 201 (9), 1355–1359. doi:10.1084/jem.20050640

Author contributions

MZ: Conceptualization, Data curation, Formal Analysis, Methodology, Software, Validation, Visualization, Writing-original draft. FW: Data curation, Formal Analysis, Software, Validation, Visualization, Writing-original draft. ZT: Data curation, Formal Analysis, Software, Validation, Visualization, Writing-original draft. XY: Data curation, Methodology, Visualization, Writing-review and editing. YL: Data curation, Methodology, Visualization, Writing-review and editing. FW: Data curation, Methodology, Visualization, Writing-review and editing. BC: Conceptualization, Writing-review and editing, Funding acquisition.

Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

Conflict of interest

Author ZT was employed by Hebei Research Institute of Microbiology Co.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2023.1256946/ full#supplementary-material

Egger, M., Davey Smith, G., Schneider, M., and Minder, C. (1997). Bias in meta-analysis detected by a simple, graphical test. *Bnij* 315 (7109), 629–634. doi:10.1136/bmj.315.7109.629

Eng, C., Kramer, C. K., Zinman, B., and Retnakaran, R. (2014). Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: A systematic review and meta-analysis. *Lancet* 384 (9961), 2228–2234. doi:10.1016/s0140-6736(14)61335-0

Fang, Y. Z., Yang, S., and Wu, G. (2002). Free radicals, antioxidants, and nutrition. *Nutrition* 18 (10), 872–879. doi:10.1016/s0899-9007(02)00916-4

Gautam, R., and Jachak, S. M. (2009). Recent developments in anti-inflammatory natural products. *Med. Res. Rev.* 29 (5), 767–820. doi:10.1002/med.20156

Habtemariam, S. (2019). Antioxidant and anti-inflammatory mechanisms of neuroprotection by ursolic acid: Addressing brain injury, cerebral ischemia, cognition deficit, anxiety, and depression. *Oxid. Med. Cell. Longev.* 2019, 8512048. doi:10.1155/2019/8512048

Higgins, J. P., Altman, D. G., Gøtzsche, P. C., Jüni, P., Moher, D., Oxman, A. D., et al. (2011). The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *Bmj* 343, d5928. doi:10.1136/bmj.d5928

Higgins, J. P., Thompson, S. G., Deeks, J. J., and Altman, D. G. (2003). Measuring inconsistency in meta-analyses. *Bmj* 327 (7414), 557–560. doi:10.1136/bmj.327. 7414.557

Hovhannisyan, Z., Treatman, J., Littman, D. R., and Mayer, L. (2011). Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. *Gastroenterology* 140 (3), 957–965. doi:10.1053/j.gastro.2010.12.002

Ikeda, Y., Murakami, A., Fujimura, Y., Tachibana, H., Yamada, K., Masuda, D., et al. (2007a). Aggregated ursolic acid, a natural triterpenoid, induces IL-1beta release from murine peritoneal macrophages: Role of CD36. *J. Immunol.* 178 (8), 4854–4864. doi:10. 4049/jimmunol.178.8.4854

Ikeda, Y., Murakami, A., Fujimura, Y., Tachibana, H., Yamada, K., Masuda, D., et al. (2007b). Aggregated ursolic acid, a natural triterpenoid, induces IL-1beta release from murine peritoneal macrophages: Role of CD36. *J. Immunol.* 178 (8), 4854–4864. doi:10. 4049/jimmunol.178.8.4854

Ikeda, Y., Murakami, A., and Ohigashi, H. (2008). Ursolic acid: An anti- and proinflammatory triterpenoid. *Mol. Nutr. Food Res.* 52 (1), 26–42. doi:10.1002/mnfr. 200700389

Kashyap, D., Tuli, H. S., and Sharma, A. K. (2016). Ursolic acid (ua): A metabolite with promising therapeutic potential. *Life Sci.* 146, 201–213. doi:10.1016/j.lfs.2016. 01.017

Kim, M. H., Kim, J. N., Han, S. N., and Kim, H. K. (2015). Ursolic acid isolated from guava leaves inhibits inflammatory mediators and reactive oxygen species in LPSstimulated macrophages. *Immunopharmacol. Immunotoxicol.* 37 (3), 228–235. doi:10. 3109/08923973.2015.1021355

Li, J., Li, N., Yan, S., Liu, M., Sun, B., Lu, Y., et al. (2018a). Ursolic acid alleviates inflammation and against diabetes-induced nephropathy through TLR4-mediated inflammatory pathway. *Mol. Med. Rep.* 18 (5), 4675–4681. doi:10.3892/mmr.2018. 9429

Li, Q., Zhao, W., Zeng, X., and Hao, Z. (2018b). Ursolic acid attenuates atherosclerosis in ApoE(-/-) mice: Role of LOX-1 mediated by ROS/NF- κ B pathway. *Molecules* 23 (5), 1101. doi:10.3390/molecules23051101

Lin, L., Yin, Y., Hou, G., Han, D., Kang, J., and Wang, Q. (2017). Ursolic acid attenuates cigarette smoke-induced emphysema in rats by regulating PERK and Nrf2 pathways. *Pulm. Pharmacol. Ther.* 44, 111–121. doi:10.1016/j.pupt.2017.03.014

Liu, J., Li, X., Lin, J., Li, Y., Wang, T., Jiang, Q., et al. (2016). Sarcandra glabra (caoshanhu) protects mesenchymal stem cells from oxidative stress: A bioevaluation and mechanistic chemistry. *BMC Complement. Altern. Med.* 16 (1), 423. doi:10.1186/s12906-016-1383-7

López-Hortas, L., Pérez-Larrán, P., González-Muñoz, M. J., Falqué, E., and Domínguez, H. (2018). Recent developments on the extraction and application of ursolic acid. A review. *Food Res. Int.* 103, 130–149. doi:10.1016/j.foodres.2017. 10.028

Luan, M., Wang, H., Wang, J., Zhang, X., Zhao, F., Liu, Z., et al. (2022). Advances in anti-inflammatory activity, mechanism and therapeutic application of ursolic acid. *Mini Rev. Med. Chem.* 22 (3), 422–436. doi:10.2174/1389557521666210913113522

Ma, J.-Q., Ding, J., Zhang, L., and Liu, C.-M. J. E. t. (2014). Ursolic acid protects mouse liver against CCl4-induced oxidative stress and inflammation by the MAPK/NF- κ B pathway. *Environ. Toxicol. Pharmacol.* 37 (3), 975–983. doi:10. 1016/j.etap.2014.03.011

Máñez, S., Recio, M. C., Giner, R. M., and Ríos, J. L. (1997). Effect of selected triterpenoids on chronic dermal inflammation. *Eur. J. Pharmacol.* 334 (1), 103–105. doi:10.1016/s0014-2999(97)01187-4

Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., et al. (2015). Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst. Rev.* 4 (1), 1. doi:10.1186/2046-4053-4-1

Moudgil, K. D., and Venkatesha, S. H. (2022). The anti-inflammatory and immunomodulatory activities of natural products to control autoimmune inflammation. *Int. J. Mol. Sci.* 24 (1), 95. doi:10.3390/ijms24010095

Nakamura, K., and Smyth, M. J. (2017). Targeting cancer-related inflammation in the era of immunotherapy. *Immunol. Cell. Biol.* 95 (4), 325–332. doi:10.1038/icb. 2016.126

Namdeo, P., Gidwani, B., Tiwari, S., Jain, V., Joshi, V., Shukla, S. S., et al. (2023). Therapeutic potential and novel formulations of ursolic acid and its derivatives: An updated review. J. Sci. Food Agric. 103 (9), 4275–4292. doi:10.1002/jsfa.12423

Nguyen, H. N., Ullevig, S. L., Short, J. D., Wang, L., Ahn, Y. J., and Asmis, R. (2021). Ursolic acid and related analogues: Triterpenoids with broad health benefits. *Antioxidants (Basel)* 10 (8), 1161. doi:10.3390/antiox10081161

Pandolfi, F., Franza, L., Carusi, V., Altamura, S., Andriollo, G., and Nucera, E. (2020). Interleukin-6 in rheumatoid arthritis. *Int. J. Mol. Sci.* 21 (15), 5238. doi:10.3390/ ijms21155238

Riley, R. D., Higgins, J. P., and Deeks, J. J. (2011). Interpretation of random effects meta-analyses. *Bmj* 342, d549. doi:10.1136/bmj.d549

Rubió, L., Motilva, M. J., and Romero, M. P. (2013). Recent advances in biologically active compounds in herbs and spices: A review of the most effective antioxidant and anti-inflammatory active principles. *Crit. Rev. Food Sci. Nutr.* 53 (9), 943–953. doi:10. 1080/10408398.2011.574802

Sarapultsev, P. A., Chupakhin, O. N., Medvedeva, S. U., Mukhlynina, E. A., Brilliant, S. A., Sidorova, L. P., et al. (2015). The impact of immunomodulator compound from the group of substituted thiadiazines on the course of stress reaction. *Int. Immunopharmacol.* 25 (2), 440–449. doi:10.1016/j.intimp.2015.02.024

Shih, Y. H., Chein, Y. C., Wang, J. Y., and Fu, Y. S. (2004). Ursolic acid protects hippocampal neurons against kainate-induced excitotoxicity in rats. *Neurosci. Lett.* 362 (2), 136–140. doi:10.1016/j.neulet.2004.03.011

Shishodia, S., Majumdar, S., Banerjee, S., and Aggarwal, B. B. (2003). Ursolic acid inhibits nuclear factor-kappaB activation induced by carcinogenic agents through suppression of IkappaBalpha kinase and p65 phosphorylation: Correlation with down-regulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D1. *Cancer Res.* 63 (15), 4375–4383.

Sun, S. C. (2017). The non-canonical NF-κB pathway in immunity and inflammation. *Nat. Rev. Immunol.* 17 (9), 545–558. doi:10.1038/nri.2017.52

Tangvarasittichai, S. (2015). Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. *World J. Diabetes* 6 (3), 456–480. doi:10.4239/wjd.v6.i3.456

Valko, M., Leibfritz, D., Moncol, J., Cronin, M. T., Mazur, M., and Telser, J. (2007). Free radicals and antioxidants in normal physiological functions and human disease. *Int. J. Biochem. Cell. Biol.* 39 (1), 44–84. doi:10.1016/j.biocel.2006.07.001

van Loo, G., and Bertrand, M. J. M. (2023). Death by TNF: A road to inflammation. Nat. Rev. Immunol. 23 (5), 289–303. doi:10.1038/s41577-022-00792-3

Woźniak, Ł., Skąpska, S., and Marszałek, K. (2015). Ursolic acid-A pentacyclic triterpenoid with a wide spectrum of pharmacological activities. *Molecules* 20 (11), 20614–20641. doi:10.3390/molecules201119721

Yang, Y., Zhao, Z., Liu, Y., Kang, X., Zhang, H., Meng, M. J. J. o. g., et al. (2015). Suppression of oxidative stress and improvement of liver functions in mice by ursolic acid via LKB 1-AMP-activated protein kinase signaling. *J. Gastroenterol. Hepatol.* 30 (3), 609–618. doi:10.1111/jgh.12723

Yu, H., Lin, L., Zhang, Z., Zhang, H., and Hu, H. (2020). Targeting NF-κB pathway for the therapy of diseases: Mechanism and clinical study. *Signal Transduct. Target Ther.* 5 (1), 209. doi:10.1038/s41392-020-00312-6